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I 
 
Abstract 
 
The liver is continuously exposed to pathogen associated molecular patterns (PAMPs) such 
as microbial ligands that are transported from the gut via the portal circulation. In liver 
disease, microbial translocation increases and patients are at risk of sepsis and poor clinical 
outcomes. The gut is not only a source of microbial ligands that interact with toll-like 
receptors (TLRs) in the liver, but also has a role in association with diet in the uptake of fatty 
acids. Fatty acids also modulate the outcome from disease.  
Diseased livers show an increase in TLRs. Under conditions of flow upon hepatic sinusoidal 
endothelium cells, stimulation of the endothelium by cell surface located TLRs increases 
adhesion of monocytes but not transmigration in an in vitro model of liver sinusoids. To 
transmigrate across hepatic endothelium efficiently, the endothelium requires priming by 
pro-inflammatory cytokines. Oleic acid can provide a suppressive effect on inflamed hepatic 
sinusoidal endothelium by reducing adhesion of monocytes. Treating monocytes with 
ligands to cell surface TLRs diminishes their ability to migrate across inflamed endothelium. 
Tumour necrosis factor α and interferon γ treatment of hepatic sinusoidal endothelial cells 
followed by treatment with lipopolysaccharides show a synergistic interaction increasing the 
expression of TLR5 and 7 beyond what is seen treatment individually by the cytokines.  
One of the fates of recruited monocytes to the liver is to differentiate into macrophages. 
Oleic acid is able to increase the expression of CD206, one of the markers of alternative 
II 
 
activation on macrophages. Alternatively differentiated liver derived macrophages show 
increased expression of TLR5.  
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Chapter 1 
1 Introduction 
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1.1 General introduction 
The burden of liver disease continues to increase in the United Kingdom and globally. 
Despite the varying aetiologies of liver diseases, they generally cause damage through a 
common pathway that leads from fibrosis to cirrhosis. However, the therapeutic options 
available to treat end staged liver disease remain limited. Currently the only effective 
treatment that results in a long-term survival advantage in end stage liver disease is 
transplantation. Liver transplantation however is constrained by the number of available 
suitable donors. Transplantation involves undergoing a major operation associated with a 
significant level of morbidity and mortality.  
There are also long term risks following successful transplantation that include those related 
to lifelong immunosuppression, rejection, infection, neoplasia and recurrence of primary 
disease.  
Those living with end stage liver disease are at a greater risk of infections and more serious 
health sequelae than the general population. The greater understanding of the inflammatory 
mechanisms resulting in end stage liver disease may lead to novel targeted treatments.  
There is an intimate relationship between the gut and the liver, the so called “liver-gut axis” 
(1). This is more than simply transporting ingested nutrients from the intestines to the liver. 
The gut is able to modulate the liver environment and its inflammatory state. The process of 
inflammation is central to the development and progression of liver disease with an 
infiltration of leukocytes from the blood stream, that include monocytes. Monocytes are not 
only implicated in propagating inflammation but also in the resolution and repair (2).  
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1.2 Overview of the liver 
The liver is a rich metabolic and glandular organ. The functions of the liver range from 
metabolism, detoxification of exogenous and endogenous substances, bile secretion, to 
clearance of microbial products from the blood (3).  Weighing typically between 1.2 to 1.8 
kg in an adult, the liver is the second largest organ in the body and is located in the upper 
abdomen, where it receives a unique dual blood supply consisting of 80% venous blood 
from the portal vein and 20% blood from the hepatic artery (Figure 1-1). This nutrient-rich 
and low oxygen tension mixture flows at a low perfusion pressure through an enormous 
network of thin-walled hepatic micro-vessels called sinusoids.  
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Figure 1-1. Dual blood supply to the liver. 
The blood supply to the liver is from the hepatic artery providing 20% of the blood and 
80% from the portal vein that arises from the gut. Image adapted from: http://biology-
diagrams.blogspot.co.uk/2014/01/liver-blood-supply_10.html 
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The liver is also considered a lymphoid organ (4) as it has a repertoire of immune cells 
involved in both innate and adaptive immunity and is a site where naïve T-cells can be 
activated (5). 
The liver is adapted to be able to deal efficiently the elimination of pathogenic organisms 
whilst being tolerant of the numerous gastrointestinal derived antigens. There are multiple 
components that lead to tolerogenic properties of the liver (Figure 1-2). This includes the 
continuous exposure of endotoxin and the presence of immunosuppressive factors such as 
IL-10, prostaglandin E2 and transforming growth factor-β. Individual cell population within 
the liver have different mechanisms as well, to form a tolerant environment. For example, 
the interaction of T-cells with sinusoidal endothelial cells leads to tolerant T-cell rather than 
effector T-cells (6).   
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Figure 1-2. The tolerogenic liver. 
Cells from the liver produce mediators such as IL-10, TGFβ and prostaglandin E2 that 
regulate the immune environment of liver. T-cells in the liver also interact with these 
mediators together with the sinusoidal endothelial cells altering to a more tolerant 
phenotype. Adapted from: Antigen-presenting cell function in the tolerogenic liver 
environment - Thompson and Knolle, 2010 (3)  
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1.3 The liver 
1.3.1 Anatomy 
Embryologically the liver is derived as a ventral outgrowth of the foregut. The anterior part 
forms the liver and intrahepatic biliary tree whereas the posterior part forms the extrahepatic 
ducts and gallbladder (7). 
The liver can be divided topographically into two lobes by the falciform ligament, the larger 
right lobe and the smaller left lobe; however, this division is of limited functional 
consequence.  Of more importance is the division of the liver based upon the division of the 
portal vein in to left and right branches. This division is used during surgery to transect the 
liver. Claude Couinaud, the French anatomist, further subdivided the liver based on its 
vasculature into eight segments; with each segment having their own independent vascular 
in and out flow in addition to biliary drainage (8). 
The microstructure of the liver can be divided into units based on the bile ducts, central veins 
or blood flow.  
The liver has a unique dual blood supply with 80% of the blood to the liver being supplied 
by the portal vein and the remainder from the hepatic artery. The portal vein is the main 
vascular drainage trunk from the gastrointestinal tract transporting matter from the gut. 
Despite providing 80% of the blood supply to the liver the portal vein only provides around 
50% of is oxygen requirements.  
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1.3.2 Functional units of the liver 
The liver can microscopically be divided into approximately 440000 functional units (9). 
This microstructure of liver is named units, triads or acini, based on the terminal branches 
of the blood vessels and bile ducts within the liver. 
The classical liver lobule consists of radiating plates of hepatocyte from a central hepatic 
vein outwards forming hexagonal units (Figure 1-3). 
The portal lobule is a triangular region made up of neighbouring central veins and centres 
on to a bile duct in the portal area. Thus, it contains portions of three adjacent classic liver 
lobules. 
The hepatic acinus of Rappaport consists of two triangular sections of adjacent classic liver 
lobules forming a diamond shape. It is based on the distribution of blood flow from a single 
portal area. It is then divided in to three zones based on the proximity of hepatocytes to the 
portal vessels and thus oxygenated blood. The periportal zone I receives the most 
oxygenated and nutrient rich blood whilst the centrilobular zone III is relatively poorly 
oxygenated. 
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Figure 1-3. The hepatic lobule. 
The hepatic lobule consists of a central draining vein from which radiates sheets of 
hepatocytes that are supplied with blood from branches of the portal vein and hepatic 
artery which form the hepatic sinusoids. Adapted from: Mescher AL. Junqueira's Basic 
Histology: Text and Atlas. McGraw-Hill Medical; 2013 
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1.3.3 Hepatic sinusoids 
Liver sinusoids are a well-connected network lined by hepatic sinusoidal endothelial cells 
together with Kupffer cells. The liver sinusoids run between plates of hepatocytes, the major 
cell type of the liver, preventing them from direct contact with the bloodstream. These 
channels are supplied by both arterial and portal blood. This blood is delivered to the central 
veins. Liver sinusoids are a unique low shear vascular environment allowing for prolonged 
interaction with the flowing blood stream and its constituents (10). 
1.3.4 Spaces of Disse 
The space of Disse is the subendothelial matrix that separates the hepatic sinusoidal 
endothelial cells and the parenchymal hepatocytes. It contains the microvilli of hepatocytes 
and stellate cells. The space allows for exchange of material from the blood carried through 
the sinusoids and the hepatocytes without directly contacting the bloodstream.  
1.3.5 Bile canaliculi 
Between hepatocytes lie the bile canaliculi with lumen protruding microvilli. Adjacent bile 
canaliculi unite to from the bile ducts, which eventually drain bile in to the gut. Bile is 
involved in the elimination of products such as bilirubin as well as aiding the digestion and 
absorption of nutrients from the gut.  
 
1.4 Capacity to regenerate 
One of the most remarkable properties of the liver is its high regenerative capability. This 
capacity to regenerate was recognised all the way back to the ancient Greeks and mentioned 
in the myth of Prometheus. Hepatocytes typically do not undergo cell division and are long 
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lived cells however they do retain the capacity to proliferate in response to insult (11).  The 
size of the liver is determined by the functional and metabolic demands placed upon it.  
 
1.5 Cell populations 
1.5.1 Hepatocytes 
Approximately 80% of the mass of the liver is made up by hepatocytes. 
They are involved in numerous functions to maintain health including: 
Protein synthesis and storage 
Carbohydrate and lipid metabolism 
Detoxification 
Synthesis of bile 
Immunity 
Hepatocytes are heterogeneous with graded zonation of their functions across the hepatic 
acinus. As blood flows through an acinus there are gradients in oxygen tension, nutrients 
and hormones. Periportal hepatocytes are thus exposed to higher concentrations of 
components carried in the blood compared to those located pericentrally (12). 
1.5.2 Hepatic sinusoidal endothelial cells (HSEC)  
Hepatic sinusoidal endothelial cells (HSEC) are highly specialised endothelial cells whose 
structure differs from other endothelial cells in that they lack a basement membrane and 
furthermore contain fenestrae, pore like structures  (13) (14). These fenestrae that vary in 
size between 100 to 200nm in diameter (15) according to their location within the liver as 
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well as exposure to other stimuli and mediators. They act as filters controlling access to the 
space of Disse. HSEC also have a high endocytotic capacity taking up substances from the 
blood by receptor mediated endocytosis (16). The combination of endocytosis and fenestrae 
make the sinusoids selective filters between the blood and liver parenchyma (15).  
Another feature of HSEC is that they can act as antigen presenting cells (APC) expressing 
major histocompatibility complexes (MHC) class I and II (17).  
During disease processes and ageing hepatic sinusoids undergo capillarisation with loss of 
fenestrae and the formation of tight junctions and Weibel-Palade bodies. Also, a basement 
forms leading to a more vascular type endothelial (18). This subsequently has adverse effects 
on the normal liver homeostasis with reduced exchange though the fenestrae and decreased 
compliance of the sinusoids resulting in portal hypertension. 
Hepatic sinusoidal endothelial cells lack significant expression of selectins, the main capture 
receptors found in other vascular beds yet are still able to capture leukocytes. Due to the lack 
of selectins in the hepatic sinusoids there is minimal rolling of leukocytes with rapid arrest 
in the low shear environment, which is at variance with the multistep adhesion cascade found 
in other vascular beds (19). 
 
1.5.3 Kupffer cells 
Kupffer cells, first observed by Karl Wilhelm von Kupffer, are the resident macrophages of 
the liver, forming around 15% of the liver cell population (20). Together with hepatic 
sinusoidal endothelial cells and stellate cells they form the non-parenchymal sinusoids of 
the liver. Their location allows them privileged and critical exposure to portal blood. This 
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key location plays a pivotal role in innate immunity by providing rapid response to 
dangerous stimuli such as bacterial products providing local and systemic defence to 
maintain homeostasis (21).  Kupffer cells have a diverse role in scavenging particles from 
the blood, antigen presentation, regeneration of the liver and tumour surveillance to name a 
few (22). They also are central in mediating hepatic injury directly and indirectly through 
the release of inflammatory substances and recruitment of other mediators. 
Due to the continuous exposure of bacterial products, Kupffer cells express low levels of 
CD14 during times of wellbeing, limiting the inflammatory response such as the production 
of TNFα, IL-6, IL-12, IL-18 and other chemokines (23). Furthermore, the anti-inflammatory 
cytokine IL-10 is secreted by Kupffer cells upon stimulation by LPS which in turns 
downregulates IL-6 and TNFα (24).  Additionally, repeated stimulation by LPS on Kupffer 
cells results in hyposensitivity to further stimulation by LPS.  
 
1.5.4 Hepatic stellate cells 
Hepatic stellate cells (HSC) are located in the space of Disse and store vitamin A in lipid 
droplets of their cytoplasm. Upon activation HSC differentiate in to myofibroblasts and lose 
their vitamin A containing lipid droplets. In the activated state, they contribute to liver injury 
to produce fibrosis via the production of extracellular matrix. Activation factors include 
TGF-β, PDGF and other proinflammatory cytokines produced by Kupffer cells. HSC 
express TLRs that may enhance the fibrogenic response (25).  
1.5.5 Liver lymphocytes 
The liver has a large resident lymphocyte population. It is estimated that the average human 
liver contains 1 x 1010 lymphoid cells (26), approximately 25% of the non-parenchymal cell 
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population (27). The presence of lymphocytes in the liver is not only associated with 
recruitment during diseased processes but are also resident in non-diseased livers. These 
resident lymphoid cells are functionally specialised for their location (28). Studies of 
lymphocyte populations in the liver show compared to peripheral blood they are enriched in 
memory T cells, activated T cells; and CD8+ T-cells that outnumber the CD4+ T-cells 
present (29). There is also a predominance of the innate immune natural killer cells (NK) 
and natural killer T-cells (NKT) allowing for a swift response to potential threats. NK and 
NKT cells can make up to 50% of the liver lymphocyte population (4).  
1.5.6 Neutrophils 
Neutrophils are the most abundant white cell type in the blood and readily track to sites of 
liver injury and stress forming an early response (30). They can clear bacteria and debris as 
well as initiate healing process (31). They are implicated in the pathogenesis of liver damage 
through uncontrolled activation. Neutrophils also modulate the hepatic immune 
environment, by interacting and tempering the function of T-cells and NK cells (32). 
1.5.7 Monocytes 
Human monocytes are highly plastic and heterogenous cells that form approximately 10% 
of the peripheral circulating leukocytes. Monocytes are derived from a common myeloid 
progenitor (from which neutrophils also are derived) in the bone marrow which gives rise to 
promonocytes. Promonocytes under the influence of M-CSF undergo two or three mitotic 
divisions over two days in the bone marrow upon which they egress into the blood stream. 
The average half-life of monocytes in the blood stream in humans is short at around 1-3 
days. The circulating pool of monocytes acts as a reservoir of the precursors to tissue 
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macrophages, dendritic cells and osteoclasts. Monocytes are able to patrol blood vessels 
using CD11a and CX3CR1 and be recruited to sites of injury and inflammation (33).  
Monocytes play key roles in both innate and acquired (adaptive) immunity. The roles of 
monocytes can be broadly divided in to antigen presentation, phagocytosis, 
immunomodulation and as a source of precursors (34). The purpose of phagocytosis by 
monocytes includes the killing of pathogens in addition to clearing up debris. Monocytes 
like neutrophils contain preformed granules which as reservoirs of enzymes that are readily 
available to take part in inflammatory reactions. However, unlike neutrophils, monocytes 
retain an ability to produce new granule proteins which is diminished in mature neutrophils.  
In the early 1980s it was recognises that monocytes functionally and phenotypically could 
be divided in to subsets (35, 36). In mice, monocytes form subpopulations and divided based 
upon their expression of Ly6C and CX3CR1. The two main subpopulations are the 
inflammatory Ly6Chi CX3CR1lo CCR2+ CD62L+ and the resident Ly6Clo CX3CR1hi CCR2- 
CD62L-. In mice each group forms approximately 50% of the circulating monocytes 
population.  
As in mice, human monocytes are also divided into subpopulations but based upon their 
expression of CD14 (LPS receptor) and CD16 (FcγRIII) cell surface receptors.  These 
subpopulations of monocytes have differential chemokine expression and functional 
properties.  
The classical resident monocyte CD14++ CD16- form approximately 90-95% of human 
circulating monocytes. The non-classical inflammatory CD14+CD16++ monocytes 
compared to CD14++ CD16- have higher expression of MHC II and lower amounts of CD11b 
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and CD33. They produce significant amounts of TNFα but little of the anti-inflammatory 
IL-10. 
The differential expression of chemokines and increasing literature suggests that the 
inflammatory monocytes are recruited initially following an insult to the tissue with 
phagocytic and proteolytic activities. During resolution, the classical monocytes are 
recruited with more of an anti-inflammatory response that promote repair and remodelling.   
A further subdivision includes a group of intermediate monocyte CD14++ CD16+ which form 
a small number of the circulating monocytes population however are present with increased 
frequency in livers and in particular diseased livers with a suggested role in hepatic 
fibrogensis (2).  
1.5.7.1 Monocyte migration to liver 
MCP-1 expression during liver injury and inflammation is upregulated (37). It is a potent 
chemotactic factor for monocytes. It is particularly more expressed in areas of fibrogenesis 
and appears to be released from biliary epithelial cells, activated stellate cells as well as 
macrophages. Additionally, release of CCR2 from the liver also provides a key signal in 
promoting the release of monocytes from the bone marrow in to the circulation and which 
then can progress in to the injured liver.  
Following adhesion monocytes undergo morphological changes involving rearrangement of 
their actin based cytoskeletons to allow for polarization and the propulsive forces required 
for migration as well formation of new adhesive interactions at the leading edge and 
disengagement at the trailing edge, thus maintaining overall adhesion to resist shear forces. 
The migration process is regulated by the Rho family of small GTPases (38). The 
morphological changes of monocytes on some endothelial cells are ICAM-1 and VCAM-1 
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dependent events (39), and LFA-1 and VLA-4 interaction with ICAM-1 and VCAM-1 
respectively modulate diapedesis across endothelium (40). 
Monocytes are able to differentiate into macrophages or dendritic cells depending upon the 
local environment. It was recognised back in the 1920s that monocytes could develop in to 
macrophages (41). Although macrophages can be derived from monocytes there is also 
evidence that their population can be maintained through local proliferation (42). Whether 
this is from local precursors, or proliferation from the existing resident macrophages, is not 
clear.  
Dendritic cells were discovered in the 1970s by Steinman and Cohn. They are specialised 
migrating antigen presenting cells. In vitro both main subtypes of monocytes are able to 
differentiate into immature dendritic cells by being cultured with IL-4 and granulocyte-
macrophage colony stimulating factor. They can then be matured by treatment with TNFα 
or TLR agonists.  
Migration of monocytes across endothelium also influences differentiation either in to 
macrophages or dendritic cells which will reverse migrate. In vitro CD14+CD16+ monocytes 
are more likely to differentiate into dendritic cells (2).  
Despite the ability of monocytes in vitro to be cultured into dendritic cells they show 
significant differences to dendritic cells isolated in vivo (43, 44). Also, this raises the 
possibility that dendritic cells in vivo do not directly differentiate from monocytes. 
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1.6 Leukocyte recruitment 
Controlled inflammation is a protective mechanism that eliminates detrimental stimuli and 
allows for repair of damaged tissue and restoration of homeostasis.  In acute inflammation, 
there is an initial recognition of infection or tissue damage by innate immune cells. This 
recognition leads to the production and release of inflammatory mediators that selectively 
recruit leukocytes locally from the vasculature (45). The locally recruited leukocytes 
eliminate the damaging agent and coordinate repair. If there is a failure to eliminate a 
persistent chronic inflammatory process develops with a change in the inflammatory 
recruited leukocytes. Chronic injury to the liver that releases inflammatory cytokines and 
the recruitment of leukocytes also sets up the conditions for the activation of hepatic stellate 
cells. Activated HSCs turn into myofibroblasts which produce the extra cellular matrix 
proteins that include collagen types I, III and IV. Liver fibrosis results from the irreversible 
deposition of collagen. 
To be able to effectively provide immune surveillance between tissues and lymphoid organs 
leukocytes need to be able to egress from the circulation. The process by which they leave 
the circulation, crossing vascular barriers, is known as the multi-step adhesion cascade (46). 
Whether leukocytes leave the circulation to enter a tissue is dependent on its interaction with 
endothelial cells and overcoming the continuous shear forces within the circulation. This 
process usually occurs in regions of microvasculature where it is easier for leukocytes to 
come out of the central flow forces that occur in vessels (47). 
In the liver, in contrast to other organs, leukocyte adhesion and migration occurs in the 
sinusoids as opposed to post-capillary venules (48).   
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1.6.1 Capture and rolling  
The classical description of the initial capture of leukocytes out of the continuous blood flow 
involves reversible tethering interactions that slows the leukocytes and results in a rolling 
motion. These tethering interactions are mediated by the member of the immunoglobulin 
superfamily or selectins group of molecules and glycosylated ligands in a “catch–bond” 
model (49, 50).  The resultant velocity reduction provides time for the leukocytes to be 
exposed to the endothelial microenvironment and any expressed factors on the vasculature 
which determines if it is activated and thus proceeds to the next step of the adhesion cascade. 
Selectins consists of a family of three type I cell surface glycoproteins named according to 
the cell type they were discovered in. They consist of short cytoplasmic tails, a 
transmembrane domain, two (L-selectin), six (E-selectin) or nine (P-selectin) consensus 
repeats that are homologous to complement regulatory proteins, an epidermal growth factor 
domain and an N-terminal lectin domain (51).  
L-selectin (CD62L) is expressed on neutrophils and monocytes, most circulating 
lymphocytes and subsets of NK cells and memory T-cells (52). E-selectin (CD62E) is 
expressed primarily on endothelium that has been exposed to inflammatory stimuli. P-
selectin (CD62P) is stored in the secretory storage granules namely, α-granules and Weibel-
Palade bodies of platelets and endothelium respectively. P-selectin is rapidly released from 
these granules and expressed on the cell surface membrane following cell activation (53).  
1.6.2 Activation and arrest 
For tethered and rolling leukocytes to be able to cross the endothelial barrier, firm and stable 
adhesion between the leukocyte and endothelium is required. In this second step of the 
adhesion cascade, leukocytes are exposed to and stimulated by chemokines presented on 
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heparin-like glycoaminoglycans on the luminal endothelial surface (54). Chemokine 
stimulation of leukocytes via G-protein coupled receptors leads to conformational change 
on the integrins of the leukocyte resulting in a higher affinity state facilitating the binding to 
their ligands which are members of the immunoglobulin superfamily (55). This firm binding 
allows leukocytes to withstand the shear forces of the circulation and arrest the flow and 
rolling. 
1.6.3 The immunoglobulin superfamily 
This family of adhesion molecules are again trans-membrane gylcoproteins that are calcium 
independent (47). They are expressed on the surface of leukocytes and endothelial cells. 
Being trans-membrane it allows for linking between the external environment and the 
internals of the cell whose functions can then be modulated.  
This family consists of ICAM-1, ICAM-2, VCAM-1 and MadCAM-1.  
1.6.3.1 ICAM-1 (CD54) and ICAM-2 (CD102) 
Intercellular adhesion molecules 1 and 2 are either present or inducible on endothelium by 
inflammatory mediators. ICAM-1 and 2 are also found on some active leukocytes. Both bind 
to the beta integrin lymphocyte function-associated antigen 1 (LFA-1, αLβ2, CD11a/CD18) 
(56).  
1.6.3.2 Vascular cell adhesion molecule-1 (VCAM-1) 
VCAM-1 is not as widely distributed as ICAM-1 but is inducible on endothelium (47) and 
found on Kupffer cells. It is involved in lymphocyte and monocyte interaction with 
endothelial cells via the integrin very late antigen 4 (VLA-4). VLA-4 undergoes 
confirmation change on leukocytes upon stimulation leading to increased binding to VCAM-
1 (57). 
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1.6.3.3 Mucosal addressin cell adhesion molecule-1 
MadCAM-1 is able to interact with lymphocytes that express α4β7 and is expressed in 
inflammatory liver disease (58). 
1.6.4 Chemokines 
Chemokines are small (eight to twelve kDa long) heparin binding chemotactic cytokines. 
They are pivotal in conducting leukocytes to the right place, at the right time to orchestrate 
immune responses in both homeostasis and inflammation. 
The classification of the over 50 human chemokines is based on their structure. Four major 
subsets have been classified based on the sequencing and presence of NH2-terminal cysteine 
motifs, namely the CXC, CC, CX3C and XC subsets.  
The CC family of chemokines in the largest group to date and consists of the first two 
terminal cysteine residues being adjacent. The CXC family have a single amino acid residue 
that separates the cysteine residues. Fractalkine (CX3CL1), the only member has 3 amino 
acid residues that separate the first two cysteine residues. The two chemokines XCL1 and 
XCL2 that makeup the XC family, both lack the first two adjacent cysteine residues.  
The CXC family can be further subdivided based on whether an ELR amino acid motif 
(glutamic acid [E]–leucine [L]–arginine [R]) at the N–terminus is present or not. The ELR 
containing chemokines are strongly involved in acting upon neutrophils. Those lacking the 
ELR motif mainly act on lymphocytes (59). 
There are over 20 human chemokine receptors which can have more than one chemokine 
ligand. Chemokine receptors are G protein coupled receptors made up of seven 
transmembrane spanning molecules coupled to heterotrimeric G proteins. Signalling by 
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chemokine receptor on leukocytes following interaction with endothelial proteoglycan 
presented chemokines during tethering and rolling, initiates conformational activation of the 
integrins to form firm adhesion to the endothelium. 
1.6.5 Integrins 
These are a group of transmembrane receptors that mediate cell to cell or extracellular matrix 
interactions. They are present on leukocytes and upon stimulation by chemokines on 
endothelial surfaces are upregulated. Integrins are heterodimers consisting of an alpha and 
beta chains.  
Integrins are a family of single pass type I transmembrane receptors of 24 αβ heterodimers. 
They are made up of non-covalent combinations of 18 alpha and eight beta subunits in 
human. They provide a link between a cell’s motility via its cytoskeleton and the 
surroundings. To this end, they have large extracellular domains to allow bind to their 
surroundings. They have short cytoplasmic tails that links to the actin cytoskeleton that less 
than 75 amino acids long except for β4 tail that is around 1000 amino acids long (60, 61). 
Through the cytoskeleton integrins can modulate beyond motility other behaviours such as 
cell survival, shape, gene expression and haptotaxis. In turn these properties have roles in 
tumourgenesis, wound healing, atherosclerosis and inflammation (61). 
Migration of cells depends on turnover of integrin adhesion with the formation of integrin 
adhesion at the leading edge of a cell with detachment at the trailing end (62). 
The heterodimeric structure of integrins regulates its affinity to ligands. The degree of 
affinity can determine the motility of a cell during the adhesion cascade from rolling during 
an intermediate affinity state to arrest when in a high affinity state (63). There are two models 
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relating to this conformational change namely the “switchblade” (64) and “deadbolt” model 
(65). The function of integrins on leukocytes as adhesion and signalling molecules is tightly 
regulated only them to deal with the unique challenges in the face of shear forces allowing 
the rapid establishment of adhesion as well as for allowing migration across endothelium 
(66). Low shear forces can stabilise the activated open confirmation of integrins maintaining 
its adhesiveness (67). 
Most leukocytes have their integrins in low affinity states (68) (exceptions include T- and 
B- cell blasts and some myeloid subsets). They become rapidly activated to bind and adhere 
to endothelium against the shear forces when they come in to contact with chemokines 
presented on the endothelial surface.  
 
1.7 Liver disease  
1.7.1 Fibrosis 
Liver inflammation and fibrosis is a highly coordinated response to tissue injury with the 
aim of repairing and restoring homeostasis. The tight control of multiple pathways 
determines whether the response is appropriate and time-limited. Key to this process are the 
cells of the immune system.  If uncontrolled, excessive irreparable damage occurs through 
extensive fibrotic scarring altering the function of the liver (69). 
Most forms of liver injury result in damage to the epithelial cells, namely the hepatocytes 
and cholangiocytes, whether this is due to viral hepatitis, fatty liver disease or alcohol. 
Inflammatory mediators are released that recruit immune cells to site of the injury to clear 
the damaged cells and debris. In addition, the recruited immune cells release further 
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mediator to amplify the immune response. Pro-fibrotic factors such as transforming growth 
factor-β (TGFβ) and IL-13 are released inducing the trans-differentiation of mesenchymal 
precursors in to myofibroblasts. TGFβ upregulated the production of collagen and α smooth 
muscle actin (70). 
Fibrosis is the accumulation of excessive extracellular matrix proteins due to chronic 
inflammation. Fibrosis in its initial stages is beneficial in limiting organ damage and 
importantly is reversible. However, the longer the damaging process goes on for, the greater 
the accumulation of avascular extracellular matrix (ECM) scar tissue. Once this ECM is 
deposited and there is reduced capacity for resolution even after the causative trigger is 
eliminated. The ability for resolution of the fibrotic scar tissue diminishes as cellular context 
in extensive scarring is lost, vascular distortion, and extensive cross-linking of ECM 
components.  
If fibrosis continues unabated it progresses towards cirrhosis where there is architectural and 
vascular distortion together with replacement of the functional parenchyma with fibrotic 
scar tissue. The consequence of cirrhosis include the functional failure of its homeostatic 
synthesis and storage functions, failure of detoxification systems, increased susceptibility to 
infections and carcinoma, and portal hypertension and resultant bleeding risk (71). 
 
1.8 The gut and bacteria in liver disease 
The liver is continually exposed to gut derived antigens and is involved in the clearance of 
toxic components. Kupffer cells and hepatocytes can recognize microbial components, 
including through Toll-like receptors leading to the release of proinflammatory cytokines 
and oxygen free radicals. An exaggerated response can lead to organ damage, hence the liver 
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has developed a mechanism of immune tolerance to avoid T-cell mediated immune 
responses against hepatocytes, even if they express antigens which are toxic for the host 
(29).  
In cirrhosis, there is impairment of the reticuloendothelial system with altered phagocytic 
capacity of cells but also due to portosystemic shunting thus bypassing the liver’s resident 
macrophage pool of Kupffer cells. Hence the circulation is not cleared of microbial products 
and cytokines. Adding to the load of microbial products in the circulation is the increased 
bacterial translocation from the intestinal lumen.  
Bacterial products include LPS which interacts with CD14-bearing inflammatory cells 
(which include monocytes-macrophages, neutrophils and other non-immune cells). CD14 
acts as a co-receptor with TLR4 for the detection of LPS. CD14 can only bind LPS in the 
presence of lipopolysaccharide-binding protein (LBP). Upon binding there is a release of 
pro-inflammatory cytokines, including TNFα, interleukin (IL)-1ß, IL-8, IL-12, cyclic 
endoperoxides, platelet activating factor (PAF), complement, tissue factor and other harmful 
mediators, which contribute to the induction of the  systemic inflammatory response 
syndrome (72). These mediatory further contribute to the circulatory disturbances that are 
common in both sepsis and cirrhosis.  
In sepsis, there is an unbalanced pro-inflammatory state in response to tissue damage or 
infection that can results in further tissue damage, organ dysfunction and death. In sepsis, 
activation of immune cells by damage-associated molecular patterns results in a cytokine 
storm that rather than being beneficial in defending the host is excessive resulting in further 
damage.  
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1.9 Immune paralysis in sepsis 
Despite the pro-inflammatory response observed in sepsis, therapies aimed at reducing 
mortality have had limited success for a number of reasons such as targeting only one part 
of a complex activation cascade with multiple layers of redundancy in the system. However, 
another concept gaining recognition is immune paralysis of immune cells including that of 
neutrophils and monocytes (73). Monocytes in the circulation in response to sepsis show 
attenuated responses to bacterial agonists and reduced expression of class II antigen 
presenting molecules to propagate the immune response (74, 75).  
The complement system becomes activated in sepsis and can further modulate the function 
of monocytes depending on their state. Monocytes that are adherent to endothelium are 
primed to produce greater quantities of inflammatory cytokines and upon exposure to 
complement factors and LPS have enhanced cytokine production (TNFα and IL-1β) (76, 
77). 
 
1.10 Pattern Recognition Receptors (PPRs) 
The first line of defence against pathogens and tissue damage is provided by the innate 
immune system. Acquired immunity is involved in later stages of infection with clonal 
selection of specific lymphocytes and generation of immunological memory (78). There are 
a group of receptors that can recognise either pathogen associated molecular patterns 
(PAMPs) or damage associated molecular patterns (DAMPs) as part of the innate immune 
system whilst discriminating from self (79).  This group of receptors include Toll-like 
receptors (TLRs) and C-type lectin receptors (CLRs). Additionally, there are cytosolic 
receptors consisting of NOD-like receptors (NLRs), RIG-I-like receptors (RLRs) and AIM2-
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Like receptors (ALRs). Activation of PRRs can result in the expression of pro-inflammatory 
and anti-viral molecules or in some cases such as activation of some NLRs and ALRs can 
result in the formation of inflammasome complexes that cleave and activate cysteine 
protease Caspase 1 which in turn proteolytically cleaves the precursor form of other proteins 
such as the inflammatory cytokines interleukin 1β and 18 thus amplifying the inflammatory 
response (80). 
Single pathogens can activate multiple PRRs to modulate the immune response. Microbial 
pathogens usually consist of multiple PAMPs and thus activate multiple PRRs. PRRs may 
detect the same PAMP. 
1.10.1 RIG-I-like receptors (RLRs) 
There are three RIG-I-like receptors based in the cellular cytoplasm, namely retinoic acid-
inducible gene 1 (RIG1), melanoma differentiation-associated protein 5 (MDA5) and 
laboratory of genetics and physiology 2 (LGP2). This group of intracellular pattern 
recognition receptors are RNA helicases that are involved in the recognition of viral 
replication by interacting with dsRNA. dsDNA is an intermediary for the replication of RNA 
viruses. RIG-1 and MDA5 contain caspase activation and recruitment domains (CARDs) 
that are able signal for a cellular response to viruses. LGP2 is required for effective RIG-1 
and MDA5 antiviral responses. RIG-1 binds preferentially to short dsRNA whilst MDA-5 
to long dsRNA. RLRs are expressed in most tissues at low levels, however upon IFNγ or 
viral exposure this is vastly increased (81-83). 
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1.10.2 Nucleotide-binding, oligomerization domain-like receptors (NLRs) 
NLRs are cytoplasmically expressed. They are made up of three domains and depending on 
their N-terminal structure subdivided into subfamilies. They are intracellular PAMP 
receptors (84).  
 
1.10.3 C-type Lectin Receptors (CLRs) 
These are a family of soluble and transmembrane receptors that contain C-type lectin-like 
domains (CTLD). C-type lectins are carbohydrate binding domains that are dependent on 
calcium for binding. They recognise fungal and bacterial PAMPs (85). 
 
1.11 Toll-Like Receptors 
In 1985 Christiane Nüsslein-Volhard of the Max Planck Institute in Tübingen, identified the 
Toll gene in the fruit fly, Drosophila and its protein product is involved in embryogenesis 
(86) and immune responses (87). In 1991 the sequence homology between the cytoplasmic 
domain of toll and the human IL-1 receptor was reported (88). Human toll-like receptors 
were first described in 1997 when Ruslan Medzhitov and Charles Janeway at Yale 
University cloned a mammalian homologue (now called TLR4) and demonstrated it as 
having a role as an innate immune system receptor (89). Subsequent discoveries 
demonstrated that these toll-like receptors form a family of pattern recognition receptors.  
 Toll-like receptors are germline-encoded type I transmembrane molecules with cytoplasmic 
domain that is similar to the IL-1 receptor and is known as the Toll/IL-1 receptor (TIR) 
domain. The extracellular domains of TLRs consist of leucine rich repeat (LRR) motifs (90).  
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They are expressed on a variety of cells, both of immune and non-immune origins. They 
recognise PAMPs on their leucine-rich ectodomain. Downstream signalling pathways are 
activated by their cytosolic Toll/interleukin (IL)-1 tails (91).  
 To date, in humans, 10 TLRs have been identified. Each TLR recognises specific PAMPs 
from a variety of sources. They however share many of the same signalling molecules and 
activation pathways to mediate proinflammatory, antibacterial and antiviral responses. 
Expression levels of TLRs in healthy adults varies from site to site and is affected by many 
factors.  
Upon recognition of a PAMP by a TLR, adaptor molecules that have TIR domains such as 
MyD88 and TRIF are recruited and initiate further downstream signals that result in the 
secretion of inflammatory cytokines, chemokines and interferons aimed at clearing the 
pathogen and recruiting leukocytes. Additionally, TLR signalling mature dendritic cells thus 
linking into the adaptive immune system (92).   
TLRs can be divided into two groups based on their compartmentalisation at the cellular 
level. One group, TLR1, TLR2, TLR4, TLR5 and TLR6 are located on the cell surface and 
can detect microbial membrane components. The others, TLR3, TLR7, TLR8 and TLR9 are 
located within intracellular compartment. They are expressed on the endoplasmic reticulum 
and trafficked to endosomes and lysosomes upon stimulation (93). By being located 
intracellularly these TLRs detect nucleic acids from viruses and other pathogens that have 
been taken up. This avoids them encountering self-nucleic acids in the extracellular 
environment and initiating autoimmunity. The extracellular nucleic acids are degraded by 
nucleases in the extracellular environment.  
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1.11.1 TLR Signalling Pathways 
Upon ligand stimulation, a downstream signalling pathway is initiated mediated by one or 
more adaptor molecules activating NF-kB and interferon regulatory factors that produce 
cytokines that act upon other defence cells.  
The response of a TLR and the binding of its PAMPs, is dependent on the recruitment of 
TIR-domain-containing-adaptor proteins. These adaptor proteins include myeloid 
differentiation factor 88 (MyD88), TIR-associated protein (TIRAP) (also known as myeloid 
adaptor like (MAL), TIR domain-containing adaptor protein inducing IFN-ß (TRIF) and 
TRIF-related adaptor molecule (TRAM). MyD88 and TIRAP produced proinflammatory 
cytokines whilst TRIF and TRAM induce IFNs.  TLRs share a common TIR domain that 
can signal via one of two main pathways. One depends on the adaptor protein myeloid 
differentiation factor 88 (MyD88) and the other does not (MyD88 independent pathway). 
The different responses mediated by distinct TLR ligands are in part explained by the 
selective use of these adaptor molecules (94). 
1.11.1.1 MyD88-dependent signalling 
All TLRs bar TLR3 signal through MyD88. Following recruitment of MyD88 to the TIR 
domain, IL-1 receptor associated kinase 4 (IRAK-4) is activated and phosphorylates IRAK-
1 and IRAK4 which associates with tumour necrosis factor- receptor associated factor 6 
(TRAF6). This leads to phosphorylation of TAK1, IκB kinase complex and MAP kinase 6. 
Phosphorylation of IκB and releases NF-κB. The activated NF-κB translocates to the cell 
nucleus and binds to response elements to the DNA of the proinflammatory genes. MyD88 
also activates the transcription factor IRF5 which to induces the synthesis of IL-6, IL-12 and 
TNF-α. IRF7 is activated by MyD88 upon activation of TLR7 and TLR9 to upregulate IFNα 
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and IFNβ to provide an antiviral response. TRIF mediated NF-κB activation is a later and 
weaker form of activation compared to direct MyD88 NF-κB activation (95). 
1.11.1.2 MyD88-independent signalling 
TLR3 and TLR4 can signal independently of MyD88. For this to occur both TLRs are 
dependent on TRIF and in addition TLR4 also requires TRAM. TLR3 activation of TRIF 
not only leads to the activation of NF-κB and inflammatory cytokine production but also of 
IRF3 and production of type I IFN (96). 
1.11.1.3 Regulation of TLR signalling 
TLR signalling is tightly regulated to prevent unnecessary activation and the subsequent 
collateral damage that may result from excessive or prolonged inflammation through these 
pathways. TLR signalling can be regulated along the signalling pathway (through protein 
phosphorylation, degradation, interaction with inhibitory adaptor molecules or 
sequestration) as well as at the receptor level (97).  
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1.11.1.4 TLR2 
It is involved in recognition of lipoproteins and peptidoglycans that are present in the cell 
walls of bacteria. It also is involved in responding to mycobacteria, fungi, hepatitis C and 
cytomegalovirus. It also recognises endogenous ligands such as heat shock proteins. TLR2 
forms heterodimers with TLR1, TLR6 and non TLR molecules such as CD36 to provide its 
range of sensing abilities.  
1.11.1.5 TLR2 heterodimers: TLR1/TLR2 and TLR2/TLR6 
TLR2 is able to recognise a variety of PAMPs from both gram negative and positive bacteria 
through forming multiple heterodimers.  
The TLR1/TLR2 complex recognises bacterial triacyclated lipopeptides, such as Neisseria 
meningitides. TLR2/TLR6 recognises diacylated lipopeptides such as found in 
Staphylococcus aureus (98). 
1.11.1.6 TLR2 and TLR6 association with CD36 
The association of TLR2/TLR6 with CD36 are not preformed as is the case with 
TLR1/TLR2 but instead induced upon ligand binding (99). Before stimulation CD36 is 
present in lipid rafts but TLR6 is not, until stimulated. This complex may be involved in 
sterile inflammation (100).   
1.11.1.7 TLR3 
TLR3 recognises double stranded (ds)DNA that is produced during the replication of ssRNA 
viruses such as West Nile virus and respiratory syncytial virus. It also recognises the 
synthetic dsDNA, polyinosinic-polycytidylic acid (poly IC) (101). 
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1.11.1.8 TLR4 
TLR4 recognises LPS from gram negative bacteria. LPS is a component of the outer 
membrane of gram negative bacteria. LPS consists of three parts, O antigen, core 
oligosaccharide and lipid A. The O antigen is a repetitive glycan polymer that forms the 
outer most part of LPS. The presence of full length O antigen chains results in a form of 
smooth LPS where as those with reduced O antigen result in rough LPS. The core 
oligosaccharide component links to lipid A. Lipid A is a phosphorylated glucosamine 
disaccharide with multiple fatty acids. It is responsible for much of the toxicity associated 
with gram negative bacteria (102). For a robust response to LPS, LPS binds to the soluble 
plasma protein LPS binding protein (LBP). This LPS-LPB complex binds to CD14 which 
delivers it to TLR4-MD2 complexes.  Without CD14 cells are unresponsive to smooth and 
low dose LPS but still respond to rough LPS and lipid A. Additionally in the absence of 
CD14 lipid A only signals using the MyD88 dependent pathway. MD2 is involved in the 
release of TLR4 from the endoplasmic reticulum and its cell surface expression in addition 
to its LPS responsiveness (103, 104). In mice alcohol induced liver injury is reduced by 
intestinal sterilisation and the subsequent reduced endotoxin levels. Also mice lacking CD14 
are protected. In humans the role of endotoxin in liver disease has been described. In the 
liver Kupffer cells in humans express CD14 (105). CD14 positive cells are increased in liver 
disease. 
 
1.11.1.9 TLR5 
TLR5 detects the conserved central part of flagellin from the flagella of bacteria (106). 
Although many non-pathogenic commensals express flagellin only pathogenic organisms 
release the monomeric form. In mice models of liver disease the activation of TLR5 by 
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flagellin  can be detrimental or protective against diet induced liver injury (107) in contrast 
to the injury that occurs by TLR4 activation in the liver.   
1.11.1.10 TLR7 and TLR8 
These are both similar binding to single stranded RNA (ssRNA) from viruses such as 
influenza and human immunodeficiency virus I (HIV-I). TLR8 does not signal in mice.  
(108) 
1.11.1.11 TLR9 
TLR9 detects the unmethylated 2’-deoxyribo (cytidine-phosphate-guanosine) (CpG) DNA 
motifs that are found in bacteria and viruses like HSV-1 and HSV-2. Vertebrates have highly 
methylated CpG DNA motifs that allows it to be differentiated (109). 
1.11.1.12 TLR10 
TLR10 is expressed in humans but the ligand is unknown (110). 
 
1.11.2 TLR tolerance 
The chronic exposure of HSEC to low levels of LPS results in relative insensitivity due to 
the reduction in TLR4 expression thus tolerance to LPS (111). This tolerogenic affect can 
also occur across TLRs. For example exposure of Kupffer cells to the TLR3 ligand poly I:C 
results in reduced sensitivity to LPS (112, 113). HSEC like Kupffer cells show tolerance to 
repetitive LPS stimulation however there is not a change in TLR4 cell surface expression. 
In addition, repetitive stimulation with LPS results in a decrease in ICAM-1 (CD54) 
expression and the ability to produce leukocyte adhesion (111). 
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1.11.3 Endogenous PAMPS 
The TLRs within the liver can also respond to endogenous signals such as those released be 
damaged cells (79). Damaged cells can release RNA (TLR3), DNA (TLR9) and high 
mobility group box protein (TLR4). Thus, there is potential for a self-sustaining state 
resulting in ongoing tissue damage.  
 
1.11.4 TLR and liver disease 
Endotoxin (lipopolysaccharides (LPS)) is largely confined to the bowel lumen. A small 
amount penetrates the intestine and then transported to the liver bound to LPS-binding 
protein, where they are cleared by Kupffer cells. 
In the western world, alcohol is the leading cause of chronic liver disease. Up to 30% of 
individuals who drink heavily will go on to develop chronic liver injury in the form of 
alcoholic hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (114).  
Alcohol increases intestinal permeability by disrupting the epithelial barrier. This then 
allows for greater translocation (115-117) of LPS which reaches the liver via the portal 
system. This greater load activates Kupffer cells contributing to alcohol induced liver injury. 
Kupffer cells also perpetuate this injury by increasing CD14 expression (118). Interruption 
of this pathway by either reducing the gut microflora with antibiotics or depleting Kupffer 
cells or their TLR4 receptors blunts liver injury (119, 120). 
Chronic alcohol ingestion not only activates TLR4 through the increased intestinal epithelial 
permeability but other TLRs are also activated (121).  
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Hepatitis B is a self-limiting condition in 80-90% of adults however in the remaining 
population it becomes a chronic condition leading to the common cause of cirrhosis and 
hepatocellular carcinoma in the world. Activation of TLR4, TLR5, TLR7 and TLR9 ligands 
inhibit HBV replication in the liver using interferon dependent pathways (122). 
Hepatitis C causes chronic infection in 70 to 80% of the population infected which once 
again can leads to cirrhosis and hepatocellular carcinoma. HCV evade the immune system 
including evasion of the TLR system. The non structural protein 3 (NS3) of the hepatitis C 
virus degrades the TLR adaptor molecule TRIF. NS3/4a protein inhibits IRF3, TBK1 and 
NF-κB activation (123, 124).  
1.11.5 Sepsis 
Sepsis occurs when there is life threating organ dysfunction in due to the inflammatory 
response to an infection (125).  Sepsis causes a significant and increasing burden worldwide 
in terms of morbidity and mortality (126). Bacteria trigger inflammatory responses not only 
by the detection of the invading bacteria itself, but also is by the host recognition of released 
endotoxins and exotoxins. Endotoxins, such as LPS, make up the cell walls of gram negative 
bacteria are released upon the breakdown of these cells. (Endotoxins also can be secreted 
(127)). Exotoxins are produced and secreted by both gram positive and negative bacteria.  
1.12 Non-alcoholic fatty liver disease 
Obesity has increased throughout the world and is not confined to only high income western 
countries. If now affects significant proportion of the population with major health and 
economic implications. 
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Obesity has implications for the health and function of the liver. Not only does it result in 
liver disease in its own right, in the form of non-alcoholic liver disease, but also exacerbates 
liver disease due to other aetiologies. For example, visceral obesity and liver steatosis 
accelerate the damage from hepatitis C (128). Also, obesity is considered as creating a state 
of chronic inflammation.  
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common form of liver disease 
and reportedly affects up to a third of the Western population (129) and up to 90% of 
morbidly obese individuals (130). It consists of a spectrum of histological changes that 
consists of simple steatosis that progresses to steatohepatitis with cellular necrosis and injury 
with an associated inflammatory infiltrate (non-alcoholic steatohepatitis (NASH)). NASH 
may progress to fibrosis and cirrhosis and their associated complications such as 
hepatocellualar carcinoma. NAFLD is increasingly being considered as the hepatic 
manifestation of metabolic syndrome that relates to insulin resistance and dysregulation of 
energy storage and utilisation. Central obesity in one of the major components of metabolic 
syndrome. The increased adipose tissue in obesity modulates fat derived factors such as 
TNFα, adiponectin and free fatty acids that alter inflammatory responses, including those of 
the liver.  
Adiponectin is protective against NAFLD by preventing fatty acid uptake and fat 
accumulation in hepatocytes. TNFα is an antagonist of adiponectin inhibiting its synthesis 
and production and increases insulin resistance. Furthermore, increased visceral adipose 
tissue results in greater lipolysis and thus free fatty acids that in the liver increase TNFα 
production, insulin resistance and promotion of NAFLD (131). 
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Additionally, obesity has negative consequences for those undergoing treatments for end-
stage liver disease by the means of liver transplantation. All cause morbidity and mortality 
of patients who are obese compared to non-obese liver transplant recipients is raised (132, 
133).  
Liver transplantation also necessitates the use of immunosuppression that causes insulin 
resistance. Calcineurin inhibitors inhibit synthesis and secretion of insulin from the pancreas 
and steroids increase insulin resistance.  They also increase blood pressure and cholesterol 
levels (134). All these factors add to the metabolic dysfunction observed in such patients. 
Furthermore, in obesity, sepsis results in increased morbidity, compared to non-obese 
patients (135). 
1.13 Fatty acids 
Fatty acids have crucial roles in making up biological cell membranes together with 
providing energy. Fatty acids are formed from a carboxylic acid with an aliphatic tail 
composed of a carbon chain skeleton with attached hydrogen atoms. Fatty acids can be 
divided in to two groups depending on whether they have carbon-carbon double bonds, the 
unsaturated group or without, saturated. The carbon-carbon double bonds can be saturated 
by adding hydrogen atoms.   
Free fatty acids are esterified into triglycerides and then enter the circulation as very low 
density lipoproteins (VLDL) or undergo β oxidation to generate acetyl-coA to produce 
energy. In NAFLD the livers role in maintaining lipid homeostasis is disrupted by the 
excessive amounts of free fatty acids delivered to it and synthesised. As a consequence of 
this exceeded capacity, triglycerides then accumulate in hepatocytes as hepatic vacuoles. 
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This disruption is further exacerbated by the metabolic syndrome and insulin resistance 
which increases lipolysis in adipose tissue and thus serum free fatty acid levels.  
It has been shown that all fatty acids do not behave same way and that in particular there is 
a division between saturated and unsaturated fatty acids. Clinically relevant outcomes 
include: 
 Mediterranean diet rich in olive oil rich in oleic acid has beneficial effects on health 
outcomes compare to diets rich in palmitic acid (136). 
 Parental nutrition is associated with parental nutrition associated liver disease (PNALD). 
Oleic acid rich nutrition has shown improved clinical outcomes in critically ill patients (137). 
 Nutrition can modulate the outcome from sepsis and depending on the composition of the 
nutrition. Critically ill patients often require some form of supplementary nutrition. Nutrition 
based on oleic acid, reduces the negative effects seen with other lipid based nutrition with 
regards to bacterial clearance (138). 
 Recruitment – Human studies have shown in peripheral mononuclear cells in those 
consuming diets rich in monounsaturated fatty acids can reduce expression of adhesion 
molecules (139). Fatty acids also have differential effects on lymphocyte cytokine 
expression. Saturated fatty acids are more potent in inducing cytokine production than 
unsaturated fatty acids (140). 
 Those with NAFLD have diets with higher fat content. Increasingly it is being recognised 
the form in which this fat intake is consumed affects liver homeostasis. NAFLD patients 
have diets high in saturated fatty acids and low in monounsaturated fatty acids (141). 
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1.14 Aim of thesis 
The liver and gut are intimately related. The gut can influence the development and 
progression of liver disease. This is possible through dietary intake that includes fatty acids 
and the presence of a rich flora of bacteria within the gut lumen that can egress into the 
portal blood stream directly to the liver.  
The hypothesis for this thesis was that TLR ligands and fatty acids, two components that 
link the gut to the liver, have a role in recruiting monocytes out of flow in an in vitro 
model of a hepatic sinusoid.  
The specific aims of this project were: 
1) Can different TLR agonists cause the recruitment of monocytes out of flow in a 
model of a hepatic sinusoid 
2) Can fatty acids alter the recruitment of monocytes from flow in a model of hepatic 
sinusoids 
3) What is the expression of TLRs in liver sinusoidal endothelial cells and liver 
derived macrophages and does this change in inflammation 
4) To develop the in vitro model of hepatic sinusoids currently used to include liver 
derived macrophages to more accurately represent what occurs in vivo 
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Chapter 2 
2 Materials and Methods 
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2.1  Ethics Statement 
Human liver tissue from the Queen Elizabeth Hospital, Birmingham, was obtained that was 
surplus or unsuitable for liver transplantation. Pathological explanted livers were also used 
with approval from the Local Research Ethics Committee (reference number 06/Q702/61). 
Blood for isolation of monocytes was obtained from healthy volunteers or patients with 
haemochromatosis (HFE) attending clinic at the Queen Elizabeth Hospital for venesection.  
2.2 Isolation of HSEC 
To isolate HSEC, a slice of approximate 50g of liver tissue from explanted human livers 
were finely chopped using sterile scalpels. The processed tissue was then transferred to a 
sterile beaker containing 20mls of PBS. To this 5mls of 0.2% collagenase solution (Sigma, 
Poole UK) was added to the beaker, covered and incubated at 37° for 20 minutes to allow 
enzymatic digestion of the tissue, till it took on a gelatinous consistency. 
The digested liver suspension was then passed through a fine mesh to another sterile beaker 
with PBS till a final volume of 200mls was obtained.  
The 200ml cell suspension was divided between 8 universal tubes and centrifuged for 5 
minutes at 550g to pellet the cells. Each pellet was re-suspended with fresh PBS, centrifuged, 
and the supernatants discarded. 
PercollTM (Amersham Biosciences, Bucks UK) gradients were created by layering 3 ml of 
33% PercollTM on top of 3mls 77% PercollTM in eight conical-bottomed centrifuge tubes. 
Each cell pellet was re-suspended in 3mls of PBS and layered on top of the PercollTM 
gradients and centrifuged at 890g for 25minutes. 
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The bands of cells (non-parenchymal cells) at the PercollTM interface were collected and 
transferred to two universal tubes and washed in PBS and pelleted. 
To remove biliary epithelial cells from the cell suspension, 50 µl of Human Epithelial 
Antibody (HEA) (50μg/ml) (Progen, Biotec, GMBH Germany) was added and incubated at 
37°C for 30 minutes. The excess antibody was then washed off with PBS and pan mouse 
Dynabeads (4 x 108 beads/ml, Dynal, UK) added. The biliary epithelia cells were then 
removed using magnetic selection. The remaining cell suspension than underwent positive 
selection with CD31 antibody (10μg/ml, DAKO, Ely UK) and Dynabeads (Dynal,UK), 
again with magnetic selection. The selected HSEC cells were incubated in Rat Tail Collagen 
(Sigma, UK) coated T25cm2 flasks (Corning, UK). The HSEC were cultured in Endothelial 
basal media (Invitrogen, Paisley UK) with 2mM L-Glutamine, 100U/ml Penicillin and 
100μg/ml Streptomycin (Sigma, Dorset UK). This was supplemented with 10% human 
serum (H+D supplies, UK) and 10ng/ml of hepatocyte growth factor (Peprotech, UK) and 
vascular endothelial growth factor (Peprotech, UK). The cells were maintained in a 5% CO2 
humidified incubator at 37°C. 
 
2.3 Isolation of human peripheral blood monocytes 
 
50mls of peripheral blood was obtained from healthy volunteers or patients attending for 
venesection for haematochromatosis at the Queen Elizabeth Hospital. This was placed in a 
50ml polypropylene tube (Corning, UK) and centrifuged at 900g for 30 minutes to create a 
buffy coat which was harvested in 10mls of the plasma supernatant. To the buffy coat – 
plasma supernatant mixture 4mls of Optiprep (60%w/v) (Axis-Shield PoC AS, Oslo, 
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Norway) was added. This was overlaid with 7.5ml of the 1.084g/ml Optiprep solution 
followed by 20mls of the 1.068g/ml Optiprep solution and finally with 2 mls of 
Gibco® RPMI 1640 medium (Sigma-Aldrich, UK). This was centrifuged at 800g for 
25minutes. The monocytes were collected from the top of the 1.068g/ml layer. 
2.4 Isolation of liver derived macrophages 
Liver derived macrophages were isolated from by a method adapted from Alabraba et al 
2007 (142). Approximately 50 gram slices of liver were finely chopped and washed in 
RPMI-1640 (Invitrogen, Paisley, UK) to remove any blood. The tissue was then transferred 
into GentleMACS C tubes (Milteni Biotec, Germany) and suspended in Gey's balanced salt 
solution (GBSS) (Sigma–Aldrich, Poole, UK) containing 0.2% (w/v) Pronase (Sigma–
Aldrich, Poole, UK) and 0.8 ug/ml DNase (Roche, Basel, Switzerland). This was incubated 
for 20minutes at 37°C then run on GentleMACS Dissociator (Milteni Biotec, Germany). 
The homogenised tissue was filtered through a fine mesh cloth. The filtrate was layered over 
a 16% Nycodenz (Axis Shield) gradient and centrifuged at 600 g for 20 min in a 25ml 
polypropylene tube (Corning, UK).  
 
The cell at the interface was collected and washed in RPMI-1640. The cells were then 
cultured in RPMI-1640 with 10% v/v heat-inactivated human serum (HD Supplies, Glasgow 
UK) in a 5% CO2 humidified incubator at 37°C. After 2 hours, the culture vessel was washed 
to remove non-adherent cells. 
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2.5 Immunohistochemistry 
 
Fixed frozen section slides of liver tissue were thawed at room temperature. A wax ring was 
placed around the liver section. The sections were fixed for 5 minutes with acetone and 
peroxidise activity blocked with peroxidise block (Dako) in humidified trays. The slides 
were washed with Tris Buffered Saline pH 7.6 (TBS) with Tween 20 (Sigma, Poole UK). 
The sections were incubated with 2.5% horse blocking serum (Vector ImmPress Kit, Vector 
Labs UK) for 20 minutes and then removed. The sections were then incubated with the 
primary antibody or respective control antibody as shown in Table 2-1. The sections were 
then washed with TBS pH7.6 and then incubated with 100μl of the secondary antibody 
(Vector ImmPress Kit, Vector Labs UK) for 30 minutes. This was then removed and washed 
twice with TBS pH7.6 and incubated for five minutes with peroxidase substrate NovaRed 
(VECTOR NovaRED Peroxidase (HRP) Substrate Kit, Vector Labs UK) and then washed 
with water. Counterstain was with Mayers haematoxylin for 30 seconds (Leica, Biosystems, 
Peterborough). The sections were mounted with Depex (DPX) (Shandon, UK). 
 
 
  
46 
 
Primary 
Antibody 
Supplier  Concentration 
used 
Antibody  Isotype 
TLR1 IMGENEX 
Corporation 
5µg/ml Rabbit Polyclonal 
TLR2 IMGENEX 
Corporation 
5µg/ml Mouse monoclonal IgG2a 
TLR3 IMGENEX 
Corporation 
5µg/ml Mouse monoclonal IgG1 
TLR4 IMGENEX 
Corporation 
5µg/ml Mouse monoclonal IgG2a 
TLR5 IMGENEX 
Corporation 
5µg/ml Rabbit polyclonal 
TLR6 IMGENEX 
Corporation 
5µg/ml Mouse monoclonal IgG1 
TLR7 IMGENEX 
Corporation 
5µg/ml Rabbit polyclonal 
TLR8 IMGENEX 
Corporation 
5µg/ml Rabbit polyclonal 
TLR9 IMGENEX 
Corporation 
5µg/ml Mouse monoclonal IgG1 
IgG1 Invitrogen 5µg/ml Mouse monoclonal IgG1 
IgG2a Invitrogen 5µg/ml Mouse monoclonal IgG2a 
Rabbit Invitrogen 5µg/ml  
Table 2-1. Antibodies used for immunohistochemistry staining of TLRs.  
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2.6 Relative quantification PCR 
RNA was isolated from cultured cells using RNeasy kit (Qiagen, Crawley UK) as per the 
manufactures instructions. The concentration and purity of RNA was measured on a 
NanoDrop spectrometer (ThermoFisher Scientific, UK). cDNA was synthesised using 
Superscript III Reverse Transcriptase kit (Invitrogen, UK). Using a NanoDrop spectrometer 
(ThermoFisher Scientific, UK) the quality and concentration of cDNA was determined. 
 
Relative quantification PCR was performed using QuantiFast SYBR Green PCR Kit 
(Qiagen, Crawley UK) with Quatitect Primer Assays (Qiagen, Crawley UK) on a 
LightCycler 480 system (Roche Life Sciences) as per Qiagen’s protocols and settings. 
GAPDH was used as the house keeping gene. The results were analysed using LightCycler 
480 SW 1.5 software.  
 
2.7 Enzyme-linked immunosorbent assay (ELISA) 
HSEC were plated in 96 well plates and cultured in media for 24 hours till confluent. The 
media was then replaced with media containing cytokines or fatty acids for a further 24 
hours. Upon completion of the incubation period, media was removed from the wells which 
were then fixed with methanol for 5 minutes which was rinsed off with PBS. The cells were 
then blocked with goat serum. After washing off the blocking serum the primary antibodies 
were added at the concentrations shown in Table 2-2 for 45 minutes. CD31 was used as a 
control. The secondary antibody after washing the cells was then added. The ELISA was 
developed using O-phenylenediamine substrate (OPD, Dako). Absorbance values at 490 nm 
was measured using a Dynatech Laboratories MRX plate reader. 
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Antibody Supplier Concentration 
IMC Mouse IgG1 Invitrogen 5µg/ml 
ICAM-1 Dako 5µg/ml 
ICAM-2 Dako 5µg/ml 
E-Selectin Dako 5µg/ml 
VCAM Dako 5µg/ml 
CD31 Dako 5µg/ml 
Secondary Goat and mouse HRP Dako  
 
Table 2-2. Antibodies used for ELISAs. 
 
 
2.8 Staining of CD68 in single cell cultures 
HSEC and or liver derived macrophages were cultured in 96 well plates. After completion 
of the culturing period the media from the wells was removed and the plated cells washed 
with PBS. The cells were fixed with ice cold methanol for 5 minutes. They were then 
blocked with 2% goat serum in PBS for 30 minutes which was then removed. CD68 (Mouse 
IgG3a) (Dako) was then incubated on the cells for 30 minutes before being washed on and 
the secondary RPE antibody (Goat anti mouse) (Dako) being added. After washing off the 
secondary antibody the cells were visualised. 
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2.9  Ibidi Flow Assays of monocytes across HSEC 
Ibidi µ-slide VI (Ibidi GmbH, Martinsried, Germany), shown in Figure 2-1, were coated 
with rat tail collagen prior to use. HSEC, from a confluent T75 flask, was re-suspended in 
500µl of media and loaded into the six individual chambers and allowed to become confluent 
prior to flow assays.  
The Ibidi slides were mounted on top a microscope (Olympus IX50; Olympus, Southend-
on-Sea, UK) within a heated 37°C chamber and connected to a DVD recorder to allow for 
off-line analysis (Figure 2-2). The slides were connected to a syringe drive (Harvard PHD 
2000, USA) set to produce a shear stress of 0.5 dynes/cm2. Monocytes were prepared at a 
concentration of 1 million cells per ml of media. 
Initially media was pumped across an individual chamber of a slide for 5 minutes to wash 
away any debris. Then the pump was switched to allow monocytes to flow across the HSEC 
for 5 minutes. After the monocytes flow was stopped, cell free media was flowed a second 
time for a further 5 minutes.  
The recordings were analysed to determine the number of adherent monocytes. Monocytes 
that are adherent to the surface of the HSEC appear phase bright whilst those that have 
migrated through the HSEC monolayer appear phase dark (Figure 2-3) (143). For each 
individual chamber, 10 different fields of view were analysed to determine the average 
number of adherent cells. This together with the flow rate was used to determine the number 
of adherent cells/mm2/106 cells perfused. Each experiment was performed a minimum of 
three times with different batches of HSEC and monocytes.  
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Figure 2-1. Ibidi µ-slide VI (Ibidi GmbH, Martinsried, Germany) with 6 channels. 
Ibidi slides were coated with rat tail collagen prior to use. HSEC were loaded in to the 
individual chambers and allowed to become confluent within 24 hours prior to stimulation 
and use in flow assays. Shown are the connectors to one of the channels. Image from: 
http://www.ibidi.com  
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Figure 2-2. Flow assay apparatus. 
The flow assay apparatus consisted of a heated incubator with a microscope (A). Shown (B 
a Ibidi slide mounted on the microscope. Image from 
http://www.jove.com/files/ftp_upload/51330/51330fig2highres.jpg 
 
 
 
Figure 2-3. Sample still from a flow assay. 
Monocytes that are adherent to the surface of HSEC appeared as phase bright whilst those 
that had migrated through the endothelial layer became phase dark. 
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2.10 Parallel chamber flow assays 
 
To flow across liver derived macrophages the Ibidi slides were replaced with parallel flow 
chambers (Figure 2-4) and the liver derived macrophages were cultured on TC25mm 
Coverslips (Cole-Palmer Instruments Company Ltd, UK) due to the inability to culture these 
cells with in Ibidi slides reliably. 
 
 
 
Figure 2-4. Parallel flow chambers 
  
53 
 
2.11 Crystal Violet Proliferation Assay 
After 24 hours of treatment media was removed from HSEC and washed with PBS twice 
and fixed with ice cold methanol. To each well 100µl of 0.1% aqueous crystal violet was 
stained with crystal violet 0.1% in PBS and 25% methanol for 1 hour, then removed with 
distilled water. The plates were then read on a Dynatech Laboratories MRX plate reader. 
 
2.12 Human Chemokine Proteome Assay 
 
Proteome Profiler™ Human Chemokine Array Kit (R&D systems) was used to analyse the 
cell culture supernatants of treated HSEC. After following the manufacturer’s instructions 
the captured proteins were visualised on Hyperfilm-ECL (Amersham Biosciences).  
Average pixel density was determined with ImageJ software (National Institutes of Health) 
and background signal subtracted.  
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2.13 Stimulations 
HSEC, liver derived macrophages or monocytes were stimulated with cytokines, TLR 
agonists or fatty acids as shown in Table 2-3. 
The concentrations used where all in the range as recommended by the suppliers. 
Peripheral blood mononuclear cells have been shown to be responsive at the 
concentrations chosen for TLR agonists through the release of cytokines (144, 145) and in 
the range in what has been used to stimulate endothelial cell lines (146).  HSEC were 
stimulated with the TLR agonists for 24 hours, a time point with which other groups have 
shown a responses to different TLR stimulations with regards to cytokine production in 
human lung endothelial and murine liver sinusoidal cells (146, 147).  Work within our 
group has shown that HSEC change they ability to recruit leukocytes after 24 hours of 
stimulation with cytokines under flow conditions (19, 148).  
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Treatment Supplier Concentration 
TLR1/2 Pam3CSK4 InvivoGen 10ng/ml 
TLR2 HKLM InvivoGen 108 cells/ml 
TLR3 Poly (I:C) InvivoGen 25μg/ml 
TLR4 LPS InvivoGen 10ng/ml 
TLR5 Flagellin InvivoGen 0.1μg/ml 
TLR6/2 FSL1  InvivoGen 0.1μg/ml 
TLR7 Imiquimod InvivoGen 2.5μg/ml 
TLR8 ssRNA40 InvivoGen 10μg/ml 
TLR9 ODN2006 InvivoGen 5μM 
TNFα PeproTech  10ng/ml 
IFNγ PeproTech 10ng/ml 
IL-4 PeproTech 10ng/ml 
Oleic acid Sigma, UK 100μM 
Palmitic acid Sigma, UK 100μM 
 
Table 2-3. Treatment for primary cells.  
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2.14 Statistical analysis 
Statistical analysis was performed with Graphpad Prism version 5. Data are presented as 
mean values ± standard error of the mean (SEM). Comparison between groups was 
performed by Student’s t test. Where more than 2 treatment conditions have been compared 
repeated measures ANOVA was used. Differences were considered statistically significant 
at a value of p<0.05. 
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Chapter 3 
3 Recruitment of Monocytes to Hepatic Sinusoidal 
Cells in Response to Toll Like Receptor Agonists 
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3.1 Introduction 
We hypothesised that activation of toll-like receptors (TLR) on hepatic sinusoidal 
endothelium by microbial ligands would play a role in modulating endothelial activation 
leading to enhanced monocyte recruitment and the potential to exacerbate inflammation. 
Because monocytes recruited from the blood are pivotal in determining the balance between 
persistent hepatic inflammation and resolution we investigated the effect of different TLR 
ligands on the recruitment of monocytes via hepatic sinusoidal endothelium.  
 
3.1.1 Modelling monocyte recruitment 
Though mechanism of recruitment of leukocytes has been well documented it is well 
recognised that the liver is an unique environment compared to other vascular beds resulting 
in distinctive differences. Thus data from the use of non-liver specific cells is not necessarily 
generalisable to the hepatic environment. Even the use of animal models has limitations with 
significant differences including metabolic rates and immune system (149). 
The lining of the liver sinusoids, HSEC, differ from other vascular beds firstly in their 
morphology with characteristic fenestrae and lack of basement membrane. They also have 
a specialised phenotype with a lack of or low expression of certain classical adhesion 
molecules such as P-selectin, E-selectin and CD31.  
In this chapter, I have used an in vitro model of hepatic sinusoids to investigate monocytes 
recruitment allowing the complex interactions that occur in vivo to be broken down.  
Previous work modelling the flow in hepatic sinusoids has used glass capillary microslides 
(150). However, several disadvantages exist, that include the challenges of preparing and 
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setting up the glass microslides prior to use. In particular ensuring the formation of a secure 
continuous endothelial monolayer is grown and not disrupted during exchanging media and 
avoiding the introduction of air bubbles during experiments. Hence commercially available 
multichannel gas permeable plastic Ibidi slides were used that have shown comparable 
results in flow assays. The use of Ibidi slides allows for modelling of vasculature beds and 
can be used to model the low shear environment of the hepatic sinusoids (143). 
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3.2 Results 
3.2.1 Ibidi slides can be used to flow monocytes without nonspecific 
adhesion 
The ability of monocytes to securely adhere to plastic is well known and this feature is 
exploited in their isolation and differentiation. 
To ensure any monocyte adhesion in the planned experiments was not simply due to 
adhesion to the plastic construct of the Ibidi slides, monocytes were flowed across the 
uncoated Ibidi slides, after washing with the basal media. Flowing monocytes across the 
uncoated Ibidi slides resulted in minimal adhesion of monocytes to the slides (Figure 3-1).  
To ensure monocytes could be pulled out of flow the slides were coated in the classical 
adhesion molecules, ICAM-1 and VCAM-1, and compared.  
There was no additional adherence of monocytes to ICAM-1 whilst being exposed to shear 
stress compared to flowing over uncoated Ibidi slides. This is in keeping with was has been 
reported in other vascular systems (151). Monocytes express the integrin LFA-1 that binds 
to ICAM-1 but in other previous studies it has been shown that to create high affinity bonds 
LFA-1 requires an activation signal (152, 153). Additionally, inflamed endothelium can 
cause reverse signalling such as by release of CD137 part of the tumour necrosis factor 
family which increases the clustering and affinity of LFA-1 to ICAM-1 (154). Furthermore 
static conditions may be a prerequisite for adhesion to occur initially between monocytes on 
only immobilised ICAM-1 (154, 155). 
Coating of Ibidi slides with VCAM-1 did result in a significant increase in the adherence of 
monocytes under flow conditions (Figure 3-1).  
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Figure 3-1. Adhesion of monocytes flowed across immobilised adhesion molecules on 
Ibidi slides.  
Ibidi slides were coated with either the classical adhesion molecules VCAM-1 or ICAM-1 
at a concentration of 10μg/ml in basal media or left uncoated (basal media alone) prior to 
being rinsed and then exposed to the flow of peripheral blood monocytes at a concentration 
of 1x106/ml. The data represents the mean ± SEM of three experiments. * p<0.05 
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3.2.2 On VCAM-1 coated Ibidi slides LPS stimulated monocytes do not 
show altered recruitment 
LPS is a potent stimulator of the immune system and of monocytes resulting in an activated 
state. This can lead to a pro-adhesive state and morphological changes of monocytes into a 
more spread state (156). Continued exposure to LPS is also able to result in a state of immune 
paralysis. To see if any of these scenarios would occur on VCAM-1 treated Ibidi slides, 
monocytes were treated with 10ng/ml LPS for one hour and then washed with fresh basal 
media. Stimulated monocytes were flown either in basal media or basal media containing 
LPS. 
Unstimulated monocytes adhered to immobilised VCAM-1 and the stimulation of 
monocytes with LPS prior to flowing did not alter the amount adhering (Figure 3-2).  
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Figure 3-2. Freshly isolated monocytes treated with LPS flowed over immobilised 
VCAM-1 in Ibidi slides.  
Freshly isolated peripheral blood monocytes were either flowed in basal media or after 
stimulation with LPS (10ng/ml) which was then washed off replaced with fresh media. The 
data represents the mean ± SEM of three experiments.  
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3.2.3 Recruitment of monocytes in an in vitro model of hepatic sinusoids 
in response to endotoxin 
To model the sinusoids of the liver to allow investigation of monocytes recruitment out of 
flow, HSEC were cultured within Ibidi slides to create a uniform monolayer. Previous work 
has demonstrated that in response to proinflammatory cytokines TNFα, the expression of 
adhesion molecules is upregulated in cultured HSEC cells and results in increased adherence 
of lymphocytes out of flow (19).  To see if monocytes behave in the same way as peripheral 
blood lymphocytes, isolated monocytes were flowed over either unstimulated HSEC or after 
HSEC that had been stimulated for 24 hours with TLR4 agonist LPS, TNFα and or IFNγ.   
IFNγ did not cause any appreciable change in adhesion of monocytes to the endothelium 
above that found in unstimulated endothelium. TNFα with or without IFNγ caused the 
maximal adhesion of monocytes. LPS also causes increased adhesion of monocytes, but of 
note fewer monocytes transmigrated through the HSEC monolayer to become phase dark in 
comparison to TNFα stimulated HSEC (Figure 3-3).  
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Figure 3-3. Adhesion of monocytes upon stimulated HSEC.  
HSEC cultured within Ibidi slides were treated for 24hours with the TNFα and or IFNγ and 
compared to the effect of the TLR4 agonist LPS at 10ng/ml.  Stimulation with TNFα and 
IFNγ was at 10ng/ml. The total adherent monocytes is made up of the phase bright 
monocytes adherent to the surface of HSEC and those that had transmigrated through the 
endothelial layer to become phase dark. Data represent mean ± SEM of 4 experiments. * 
p<0.05 
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3.2.4 LPS is a more potent stimulator of monocytes recruitment to HSEC 
than Monophosphyoryl lipid A 
Monophosphyoryl lipid A (MPL) which is derived from the lipid A part of LPS is considered 
a non-toxic TLR4 ligand. To see if the different effect of LPS compared to TNFα is a unique 
effect of LPS or the stimulation through TLR4 pathways the experiments were repeated with 
MPL.  
MPL stimulated HSEC did result in recruitment of monocytes but to a lesser extent than 
observed with LPS. Monophosphoryl Lipid A (MPL) is a TLR4 agonist formed by 
hydrolysis the diphosphoryl Lipid A component of LPS. These changes results in a decrease 
in the toxicity compared to unaltered lipid A so that there is a reduction in proinflammatory 
cytokines released after exposure (157, 158). This reduction in toxicity is to such an extent 
that it can be used in clinical use as a vaccine adjuvant in humans (159, 160). The reduction 
in recruitment of monocytes is in keeping with this reduced toxicity compared to LPS. Other 
work has shown MPL and LPS are able to differentially activate the anti-inflammatory genes 
such as IL-10 (158). Though the total number of adherent monocytes on MPL stimulated 
HSEC was less than upon LPS stimulation the same lower proportion of transmigration was 
seen (Figure 3-4).  
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Figure 3-4. Adhesion of monocytes upon MPL versus LPS treated of HSEC  
HSEC cultured within Ibidi slides were treated for 24 hours with either the TLR4 agonist 
LPS at 10ng/ml or MPL at 1μg/ml.  Freshly isolated peripheral blood monocytes were then 
flowed across. Data represent mean ± SEM of 4 experiments. * p<0.05 
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3.2.5 Tolerance: Continued prolonged exposure of HSEC in vitro to LPS 
results in reduced monocyte adhesion however they are still 
responsive to repeated stimulation. 
Because the liver is continuously exposed to bacterial products via the portal vein I checked 
whether HSEC are still responsive despite continued stimulation. Murine work has shown 
hypo-responsiveness of monocytes on repeated exposure to LPS due to reduced expression 
of CD14 and TLR4 on repeated exposure whereas sinusoidal endothelial cells retain their 
expression of these receptors (111). As a result, pre-treatment of mice with TLR4 agonist in 
caecal ligation and puncture model of septic shock is able to induce endotoxin tolerance by 
reducing subsequent cytokine and chemokine release (161) and consequently neutrophil 
recruitment in to the liver, potentially limiting host damage.  
To assess whether a shorter exposure to LPS rather than the 24 hours used in the flow assay 
experiments would result in a different amount of adhesion of monocytes a 4 hour time point 
was used. Confluent monolayers of HSEC within Ibidi slices were treated with LPS for 
either 4 or 24 hours prior to flowing monocytes across. Freshly isolated peripheral 
monocytes were then flowed over the HSEC. HSEC that had been stimulated for 4 hours 
produced the maximal amount of adhesion that reduced by 44% on HSEC that had been 
stimulated for 24 hours (Figure 3-5).   
Re-stimulating HSEC that had been treated with LPS for 24 hours with fresh media 
containing LPS resulted in boosting monocytes recruitment, showing they are still 
responsive, however not back to levels seen on short stimulation of naive HSEC (Figure 
3-5).  
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Figure 3-5. The effect on monocytes recruitment upon different length of LPS 
stimulation of HSEC. 
HSEC were cultured within Ibidi slides and were treated for either media or the TLR4 
agonist LPS at a concentration of 10ng/ml. LPS treatment was 4 or 24 hours immediately 
prior to flowing freshly isolated monocytes. A further group of HSEC that had been 
stimulated for 24 hours were re-stimulated for a further 4 hours with fresh LPS containing 
media. Data represent mean ± SEM of 4 experiments. P<0.05 
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3.2.6 Pertussis toxin treated monocytes reduces the proportion of 
transmigrating across TNFα but not LPS activated HSEC  
To investigate the role of G-coupled proteins in the role of adhesion and transmigration of 
monocytes on activated HSEC, monocytes were incubated with pertussis toxin. Pertussis 
toxin is a protein exotoxin from the bacterium Bordetella pertussis. This exotoxin is taken 
up by cells and prevents heterotrimeric Gαi proteins from interacting with G protein coupled 
receptors and their subsequent signalling pathways which affects the production of 
chemokines, which are important in leukocyte recruitment.   
Lymphocytes blocked with pertussis toxin then flowed over chemokine activated HSEC 
results in reduced adhesion (162). This is a similar finding to what happens with the pre-
treatment of CD16+ monocytes with pertussis toxin, with reduction in both the number of 
adherent monocytes and the number transmigrated, though with a much more profound 
effect on transmigration (163). 
In these experiments using unselected monocytes treated with pertussis toxin to inhibit G-
protein coupled receptors reduced the number of monocytes transmigrating and becoming 
phase dark only when flown over HSEC that had been stimulated with TNFα with or without 
IFNγ but not IFNγ alone. Pertussis toxin did not reduce the total number of adherent 
monocytes whatever the cytokine stimulation of the HSEC. No effect was seen when 
pertussis toxin treated monocytes were flown over LPS stimulated HSEC. This suggests that 
the initial adhesion of unselected peripheral blood monocytes is G-couple protein 
independent whilst a significant proportion of transmigration on TNFα activated HSEC is 
partially dependent on G-couple proteins (Figure 3-6).  
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Figure 3-6. Pertussis toxin treatment on monocytes recruitment to stimulated HSEC 
Monocytes were treated with pertussis toxin at a concentration of 100ng/ml to inhibit G-
coupled protein signalling. They were then flowed across HSEC cultured within Ibidi slides 
that were treated for 24 hours with the LPS, TNFα and or IFNγ. Data represent mean ± SEM 
of 4 experiments. *p<0.05 
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3.2.7 Primed endothelium increases transendothelial migration 
Liver disease is often considered as two or multiple hit process (164). The second or 
subsequent hit includes the exposure to gut derived LPS. It has been repeatedly shown that 
germ free raised mice have attenuated liver disease progression (165).  
The previous experiments have shown that HSEC treated with LPS alone prior to the flow 
of monocytes does not result in as much transmigration compared to TNFα treated HSEC. 
As liver disease progresses the serum levels of TNFα of affected individuals increases (166, 
167).  
Therefore, to assess if priming with inflammatory cytokines prior to exposure of LPS would 
alter the pattern of recruitment of monocytes, HSEC were treated with the proinflammatory 
cytokines TNFα and IFNγ prior to stimulation with LPS within Ibidi slides.  
The prior treatment of HSEC with TNFα and IFNγ followed by LPS stimulation increased 
significantly the number of transmigrated monocytes compared to only treating with LPS 
(Figure 3-7).  
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Figure 3-7. Priming of HSEC prior to LPS stimulation 
HSEC cultured within Ibidi slides were primed for 24 hours with TNFα and IFNγ or media 
only. The media after 24 hours in the Ibidi slides was then exchanged with LPS containing 
media. Freshly isolated peripheral blood monocytes were then flowed across. Data represent 
mean ± SEM of 4 experiments. *p<0.05 
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3.2.8 Pertussis toxin reduces transmigration of monocytes on TNFα and 
IFNγ primed HSEC treated with LPS 
Previous experiments have demonstrated that priming HSEC with TNFα with IFNγ results 
in around half of peripheral blood monocytes transmigrating under conditions of flow. 
Furthermore, the low proportion of monocytes transmigration across LPS treated HSEC is 
increased by first priming with TNFα and IFNγ. Pertussis toxin treated monocytes showed 
reduced transmigration across TNFα and IFNγ activated HSEC. To investigate the effect of 
G-coupled signalling on LPS treated HSEC that had been primed by TNFα and IFNγ was 
tested.  
When HSEC had been primed with TNFα and IFNγ prior to stimulation with LPS the 
reduced monocyte transmigration of pertussis toxin treated monocytes was maintained 
without affecting the total number of adherent monocytes (Figure 3-8). 
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Figure 3-8. Adhesion of pertussis toxin treated monocytes on primed HSEC treated 
with LPS. 
Monocytes were treated with pertussis toxin at a concentration of 100ng/ml to inhibit G-
coupled protein signalling. They were then flowed across HSEC cultured within Ibidi slides 
that were stimulated with LPS after first being primed TNFα and IFNγ (compared to no 
priming). Data represent mean ± SEM of 3 experiments. *p<0.05 
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3.2.9 Cell surface located TLRs increase monocyte adhesion 
So far, the experiments showed that the TLR4 agonist LPS as well as MPL are able to induce 
adhesion of flowing monocytes on to HSEC. In humans, there are, to date 9 well described 
TLRs. (TLR10 does not have a known ligand specificity) (168). To investigate the effect of 
stimulation with other TLR agonist, HSEC was stimulated with known TLR agonists prior 
to flowing peripheral blood monocytes.  
Treatment of resting endothelium with ligands to TLRs 1, 2, 4, 5 or 6 for 24 hours resulted 
in increased adhesion of monocytes under flow. Activation of TLRs 3, 7, 8 or 9 with specific 
ligands had no significant effect on adhesion or migration (Figure 3-9). Of note TLRs 1, 2, 
4, 5 or 6 are all located on cell surfaces and all signal down MyD88 pathway. TLRs 3, 7, 8 
and 9 are compartmentalised intracellularly to detect nucleic acids.  
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Figure 3-9. Adhesion of monocytes to HSEC stimulated with TLR ligands. 
HSEC were stimulated with TLR ligands for 24 hours and then freshly isolated monocytes were flowed across. The data represent the mean 
± SEM of 4 experiments. P<0.05 
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3.2.10 Inflammatory priming of HSEC increases transendothelial 
migration in response to bacterial sensing TLRs 
As the previous experiment showed, stimulation of HSEC with microbial components that 
interact with cell surface TLRs supports adhesion out of flow of monocytes. However, few 
of the adherent monocytes transmigrated as previously seen with HSEC treated with LPS. 
To see if priming HSEC with proinflammatory cytokines beforehand would alter this state, 
HSEC was treated with TNFα and IFNγ before further stimulation with TLR ligands. The 
priming of HSEC with the proinflammatory cytokines TNFα and IFNγ resulted in allowing 
adhered monocytes to transmigrate compared to HSEC treated with only TLR ligands. The 
proportion of monocytes transmigrating on TNFα and IFNγ pre-treated HSEC was similar 
no matter which cell surface TLR agonist was used subsequently. The priming of HSEC 
with TNFα and IFNγ prior to stimulation with bacterial ligands of cell surface TLRs resulted 
in increased transmigration as seen previously with LPS and thus the effect was not confined 
only to TLR4 stimulation (Figure 3-10).  
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Figure 3-10. Adhesion of monocytes to primed HSEC stimulated with TLR ligands  
HSEC were primed with TNFα and IFNγ prior to stimulation with TLR ligands within Ibidi 
slides. Freshly isolated monocytes were flowed across the HSEC and monocyte adhesion 
assessed. The data represent the mean ± SEM of 3 experiments 
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3.2.11 LPS stimulation of monocytes diminishes their ability to 
transmigrate across inflamed endothelium 
 
We also looked at what occurred when monocytes were treated with LPS as opposed to the 
endothelium. On unstimulated endothelium, LPS treated monocytes were no more 
adhesive than untreated monocytes. However, when the experiment was repeated upon 
TNFα and IFNγ treated HSEC, the treatment of monocytes diminished the migration seen 
of adhering monocytes by almost 70% (Figure 3-11). 
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Figure 3-11. Recruitment of LPS treated monocytes upon inflamed endothelium. 
Monocytes were treated with LPS for 1 hour after isolation and then either flowed across untreated HSEC or after stimulation with TNFα 
with IFNγ or LPS in Ibidi slides. The data represents the mean ± SEM of three experiments. * p<0.05
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3.2.12 Cell surface TLR stimulation of monocytes reduces transmigration 
of monocytes across activated endothelium 
Having seen the effect upon LPS treated monocytes recruitment upon inflamed HSEC we 
went on to investigate the effect of other cell surface TLR stimulation of monocytes upon 
TNFα and IFNγ treated HSEC modelling inflamed endothelium.  
When unstimulated monocytes were flowed over TNFα and IFNγ stimulated HSEC as 
expected resulted in an increase in total adhesion of monocytes and this was unaffected by 
treating the monocytes with used TLR agonists. However, the proportion of monocytes 
transmigrating across the endothelium reduced by approximately on average by around 50% 
and not by only LPS (Figure 3-12).  
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Figure 3-12. Treatment of monocytes with bacterial ligands prior to flowing across 
HSEC.  
Freshly isolated peripheral blood monocytes were treated with the cell surface TLR agonists 
Pam3CSK, HKLM, LPS, Flagellin or FSL-1. They were then flowed across HSEC or TNFα 
and IFNγ treated HSEC in Ibidi slides. The data represent the mean ± SEM of 3 experiments.  
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3.3 Discussion  
A defining feature of inflammation is the recruitment of innate immune cells. This includes 
the recruitment of monocytes. Studies have shown that the recruitment of monocytes in 
response to liver damage perpetuate the inflammation as well as expanding the macrophage 
pool within the liver (169).  
To investigate the mechanisms of leukocytes recruitment in the liver, our laboratory has 
developed specialised techniques. The vascular beds within the liver are unique and 
specialised allowing it to perform its multitude of functions. Thus, it is not possible to 
generalise the results from studies of other vascular beds. The use of animal studies though 
helpful, there remains major differences when compared to humans. The ability to isolate 
human HSEC and the ability to flow leukocytes across them at low shear pressure to mimic 
the conditions within hepatic sinusoids, allows breaking down the complex interactions 
involved in multicellular interactions. The importance of shear stresses is well recognised to 
alter recruitment of leukocytes out of flow. Previous work in our laboratory has 
demonstrated the usefulness of the use of Ibidi slides in investigating recruitment of 
lymphocytes (143). In this thesis we have gone on to look at monocytes recruitment. 
Monocytes are well known to adhere to plastic, a fact exploited in some methods of isolation. 
The observation of the lack of adhesion whilst flowing monocytes across the Ibidi slides but 
when given the appropriate signals could be captured out of flow and change phase allowed 
the model to be used for further experiments.  
We have shown that LPS stimulation of HSEC is able to recruit monocytes out of flow and 
for them to become adherent. This same finding was also seen with stimulation with other 
agonists of cell surface located TLRs. However, the same was not true with the TLRs 3, 7, 
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8 and 9 that are intracellular and involved in detecting nucleic acids. Though the cell surface 
group of TLRs resulted in increased adhesive properties to HSEC this did not translate to 
increased transmigration across.  
The importance of this finding is that the liver is continuously exposed to microbial products 
from the gut, yet efficiently clears them without producing an overwhelming local 
inflammation within the liver and prevents systemic spread and subsequent disseminated 
inflammation in the body. So, in this model of hepatic sinusoids where there is stimulation 
by microbial components that interact with cell surface TLR ligands, HSEC support the 
adhesion but not the transmigration of flowing monocytes. This may give an insight to what 
occurs physiologically. In humans, this may be a mechanism that prevents accumulation of 
monocytes into the liver parenchyma and potentially causing unnecessary harm particularly 
when the portal blood stream contains microbial products derived from the gut are 
continuously in contact with the hepatic sinusoids.  
In keeping with previously published data, monocytes, similar to leukocytes flowing over 
HSEC did not require a rolling step to be captured out of flow in keeping with the lack of E-
selectin in hepatic sinusoids (170).  
Work in our laboratory, has demonstrated TNFα to significantly activate HSEC to result in 
a pro-adhesive state. Further work from the laboratory has shown the addition of IFNγ to 
stimulate HSEC increases the amount of adhesion molecules expressed but not the pattern 
of expression (162). IFNγ together with TNFα is able to increase the secretion of the CXCR3 
ligands CXCL9, 10 and 11. Despite the ability of IFNγ to increase the expression of adhesion 
molecules and secretion of CXCR3 ligands the lack of any major increase in adhesion and 
transmigration when compared to TNFα alone may be partly due to the experiment being 
86 
 
performed under flow conditions. It has previously been shown that flow can attenuate the 
effects of IFNγ through inhibition of STAT1 activating the target chemokine genes (171). 
In this model when HSEC were primed by TNFα and IFNγ simulating the presence of pre-
existing inflammation, further stimulation with bacterial products was able to promote 
transmigration. This may reflect the hepatic infiltration by monocytes that occurs in liver 
disease as part of a two/multi hit process exacerbating and perpetuating hepatic 
inflammation. 
A feature of LPS stimulation is its ability to induce a state of tolerance resulting in 
diminished responses upon repeated stimulation. Studies have shown the liver sinusoids 
made up of HSEC with Kupffer cells gain tolerance to endotoxin and go into a refractory 
state (172). Monocytes also have the ability to become tolerant. The experiments performed 
here showed that this ability remained in this flow system, in that repeated stimulation of 
HSEC by LPS had diminished adhesion compared to the initial stimulation, but nevertheless 
still retain the ability to respond.  
The mechanisms for the tolerance vary by cell type. Monocytes upon exposure to LPS are 
known to down regulate TLR4 expression. Unlike as described in monocytes and 
macrophages there is no down-regulation of surface expression of TLR4 in HSEC upon 
exposure to LPS (111).  However, HSEC gain LPS tolerance by reduced nuclear localization 
of NFkB (111).  
In vivo, the tolerance effect of LPS is likely to be a result of multiple interactions between 
cell types. HSEC is likely to be modified by the resident Kupffer cells which also are 
tolerised by LPS and release IL-10 that can suppress inflammation. 
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Within a matter of a few hours following stimulation with LPS, monocytes produce 
significant pro-inflammatory cytokines. The anti-inflammatory cytokine IL-10 production 
peaks after 24 to 48 hours(173). IL-10 together with TGFβ and prostaglandin E2 desensitise 
monocytes to further LPS stimulation (174). The effects of IL-10 on monocytes includes the 
suppression of pro-inflammatory cytokine release, antigen presentation and production of 
free oxygen radicals. 
Though in these assays stimulation of HSEC or monocytes with LPS reduced transmigration 
there is still the potential of harm. Activated adhered monocytes on endothelium can damage 
the endothelium by releasing pro-inflammatory mediators that include IL-1 and IL-6, 
eicosanoids, reactive oxygen species (ROS), platelet activating factor, and nitric oxide (NO) 
(175). 
The use of the flow system with Ibidi slides has a number of draw backs. Firstly, the HSEC 
and monocytes used were from different donors and thus incompatibility interactions could 
have unknown effects in this system. This system was also used in normoxic atmospheric 
oxygen levels. However the liver has a lower oxygen tension and this has been demonstrated 
to alter HSEC structure and adhesion molecule expression (176). Also flowing across a 
monolayer of HSEC removes these cell from the influences of the liver environment and the 
interaction with other hepatic cells that modulate milieu. 
For the timings of stimulating cells times of 4 and 24 hours were uses for practicalities of 
running the flow assays. However, this potentially could be missing the maximal effects of 
the treatments. LPS in health can be eliminated from the circulation in minutes by the liver, 
though its effects can last for a longer time (177). Using the same length of exposure for all 
the different treatments ignores the kinetics of the different stimulations.  
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The concentrations used for stimulations were chosen on the basis of what is known from 
other studies to be able to stimulate monocytes and endothelial cells, but this does not 
necessarily corollate with what is possible physiologically. Though levels of LPS in humans 
during liver disease can reach high levels they are generally lower than used in these 
experiments (178). However, the concentration of flagellin used was at a levels that occurs 
physiologically but can increase in disease (179). The importance of different concentrations 
has been demonstrated with flagellin’s ability to potentially be beneficial at low doses in 
aiding bacterial clearance by neutrophils in a burns sepsis model (180). However high levels 
of flagellin result in liver injury (181). 
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Chapter 4 
4 The Expression Of TLRs, Adhesion Molecules 
And Cytokines In HSEC In Response To 
Inflammation 
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4.1 Introduction 
Having seen the functional consequences of TLR ligands stimulation upon monocyte 
recruitment we have gone on to look at some of the changes that occur in response to 
inflammation and disease. TLRs are pivotal in the development and perpetuation of liver 
disease. It has been increasingly recognised that it is not only TLR4 that is involved but also 
the other members of the TLR family are increasingly implicated. In the previous chapter 
we have shown that any of the TLR ligands that interact with cell surface TLRs are able to 
cause the adhesion of monocytes on to HSEC. 
In this chapter, we have looked for expression of TLRs in the liver and HSEC. We have also 
looked at changes in cell surface HSEC adhesion molecules and released cytokines upon 
activation that may help explain the lack of monocyte transmigration when treated with cell 
surface TLR ligands.  
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4.1.1 Diseased liver tissue from explanted livers shows increased 
expression of TLR2, TLR4, TLR5, TLR6 and TLR9 
 
Though current published literature report the presence of the different TLRs within the 
liver, there is variance as to which TLRs are expressed. To see if we could demonstrate the 
presence of TLRs in livers immunohistochemisty staining was performed. Sections from 
normal donor livers and those from livers diseased by either alcoholic liver disease, 
autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis were 
stained. (TLR1, 3, 7 and 8 staining was attempted but did not produce reproducible staining. 
Attempts were made to use different antibody concentrations and staining on lymph nodes 
that express these TLRs.)  
The diseased liver sections showed visibly higher staining of TLRs in particular of TLR2, 
TLR4, TLR5, TLR6 and TLR9. Most of the increased staining appeared to be related to the 
fibrotic scars (Figure 4-1).  
Though there was positive staining in diseased livers with certain antibodies for TLRs great 
care must be taken in interpreting the results. Staining with antibodies for TLRs often fail to 
recognise their designated TLR proteins in their native forms on cells (182).   
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TLR4 – 20x
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TLR5 – 20x
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Figure 4-1. Staining of normal and disease liver section for expression of TLRs.  
Frozen sections of liver from normal or diseased livers were stained for TLRs. Isotope control staining was performed to look for non-
specific staining (images not shown).  
TLR9 – 20x
Autoimmune 
Hepatitis
Primary Biliary Cirrhosis
Alcoholic Liver Disease
Primary Sclerosing Cholangitis
Normal Liver
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4.2 Inflammatory cytokines alter the expression of TLRs on 
HSEC at a mRNA level 
 
To assess what occurs in the sinusoids to HSEC when exposed to inflammatory cytokines, 
relative quantification PCR was used to determine what would happened to relative TLR 
mRNA levels following exposure to classical inflammatory cytokine TNFα and IFNγ.  
The role of LPS was also investigated as though TLRs respond to specific ligands, a number 
of studies have shown that LPS (as well as other TLR ligands) are able to alter the expression 
of other TLRs through cross talking (183). This means that TLR ligands can modulate 
unrelated TLR receptors. To see if HSEC would show altered mRNA expression of 
unrelated TLRs to LPS, PCR was performed on LPS treated HSEC.  
IFNγ upregulated the expression of TLR3 and downregulated TLR2 and 9. It did not 
increase the expression of any of the cell surface bacterial sensing TLRs.  
TLR2 had the greatest increase in expression in response to TNFα and LPS. Interestingly 
the effect of TNFα and LPS on the levels of TLR1 and TLR6, which associate with TLR2 
to form heterodimers, were far more modest.   
TLR4 expression in HSEC was reduced by stimulation with TNFα, IFNγ and LPS, 
individually.  
The expression of TOLLIP, a negative regulator of TLR signalling, was unaffected by the 
presence of inflammatory cytokines (Figure 4-2).  
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Figure 4-2. Relative Real Time PCR on 
cytokine stimulated HSEC.  
HSEC were stimulated with TNFα, IFNγ, or LPS. 
Relative Real Time PCR was carried out for 
mRNA expression of TLRs and TOLLIP using 
SYBR green and GPADH as the house keeping 
gene with all performed in triplicate. The relative 
expression is presented against unstimulated 
HSEC. The data represents the mean ± SEM of 3 
experiments each with a different donor HSEC. 
*p<0.05 
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4.2.1 Treatment with combination of cytokines has a greater effect on TLR 
mRNA expression in HSEC 
Real time PCR was also performed on HSEC after treating with the combination of TNFα 
with IFNγ for 24 hours with or without further LPS stimulation afterwards.  
The combination of TNFα with IFNγ resulted in a dramatic rise in the expression of TLR7 
compared to the individual cytokines alone. The priming of HSEC with TNFα and IFNγ 
prior to LPS stimulation caused a large increase in the expression of TLR3 and TLR5 beyond 
what was seen without the additional LPS stimulation, demonstrating some sort of 
synergistic effect (Figure 4-3).  
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Figure 4-3. Relative Real Time PCR on 
primed HSEC in response to LPS.  
HSEC were stimulated with TNFα and IFNγ, 
with then media with or without LPS. Relative 
Real Time PCR was carried out for mRNA 
expression of TLRs and TOLLIP using SYBR 
green and GPADH as the house keeping gene 
with all performed in triplicate. The relative 
expression is presented against unstimulated 
HSEC. The data represents the mean ± SEM of 3 
experiments each with a different donor HSEC. 
*p<0.05 
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4.2.2 Priming HSEC with TNFα and IFNγ prior to LPS stimulation does 
not alter the expression of classical adhesion molecules 
 
To assess the effect of the inflammatory mediators on adhesion molecule expression, Cell 
based ELISAs were performed on HSEC that had been stimulated with TNFα, IFNγ or LPS. 
IFNγ did not alter the expression of any of the adhesion molecules tested. Levels of CD31 
were also assessed as a control as previously shown stimulation with inflammatory cytokines 
showed no increase (19, 148). TNFα and LPS increased the expression of ICAM-1, E-
selectin and VCAM-1 but not ICAM-2.  
Next we went on to see if priming the HSEC for 24 hours with TNFα, IFNγ and LPS before 
further stimulation with LPS had an effect upon the adhesion molecules. E-Selectin was 
increased upon exposure to LPS with any of the priming inflammatory cytokines. 
Expression ICAM-1 and VCAM-1 was increased on stimulation with LPS, only if the HSEC 
had been primed with IFNγ. Priming with the TNFα and IFNγ combination did not alter 
adhesion molecule expression (Figure 4-4). 
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Figure 4-4. Expression of adhesion molecules on HSEC in response to LPS following 
priming.  
HSEC were treated with basal media alone or supplemented with LPS, TNFα and/or IFNγ. 
They were then stimulated with LPS. Adhesion molecules were assessed by cell based 
ELISA. Data represents mean ± SEM of the absorbance of three experiments on different 
batches of HSEC performed in triplicate. *p<0.05 
108 
 
4.2.3 HSEC release distinctly different chemokine signals in response to 
different proinflammatory stimuli 
Chemokines, are a family of small secreted molecules, that are involved in a wide variety of 
immune functions including leukocyte trafficking and activation. Chemokines are 
classically considered chemo-attractant molecules. In the previous experiments, different 
proinflammatory chemokines demonstrated different effects on flowing monocytes across 
HSEC, namely in response to LPS monocytes became adherent but did not transmigrate 
whilst they did migrate across HSEC in response to TNFα. To further assess the differential 
migration of monocytes across hepatic sinusoidal endothelial cells in response to 
proinflammatory stimuli, the chemokines released by the HSEC was assessed following 
proinflammatory stimulation with LPS, TNFα and IFNγ. In the previous flow studies IFNγ 
did not produce any significant adhesion of monocytes in flow compared to TNFα and LPS. 
The factors released was analysed using a cytokine proteome profiler array (Figure 4-5).  
A number of chemokines were raised in TNF and LPS treated HSEC compared to HSEC 
treated with IFNγ or media only. The chemokines that were raised were in TNFα and LPS 
stimulated HSEC compared to IFNγ or media treated HSEC included:  
ENA 78 (CXCL5) 
Fractalkine (CX3CL1) 
GROα (CXCL1) 
I-309 
MIP-3α 
MCP-1 
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GROα and MCP-1 have well described roles in the recruitment of monocytes, and both are 
upregulated on inflamed endothelium. GROα is immobilised by heparin proteoglycans 
where as MCP-1 is released and present predominantly in a soluble form. GROα has 
previously been shown to be involved in the arrest of monocytes from flow acting on 
CXCR2 on monocytes. MCP-1 acting on CCR2 and CXCR2 (184) present on monocytes 
has also been shown to be able to cause arrest of flowing monocytes on vascular endothelium 
(185) and support spreading and migration (184). Elevated levels of MCP-1 have been found 
in hepatitis with an associated accumulation of an inflammatory infiltrate (186). Fractalkine 
has been shown to be upregulated on other endothelium in response to inflammatory 
cytokines again with the ability to capture monocytes (187). MIP3α (CCL20) that acts 
through CCR6 on monocytes has also been revealed to be chemoattractant to monocytes 
(188). 
Epithelial cell-derived neutrophil-activating peptide 78 (ENA-78), a CXC chemokine, 
CXCL5 is usually not considered a monocytes chemoattractant, however upon citrullination 
it does acquire the ability to recruit monocytes (189). 
CCR8 a receptor on monocytes (190) to the ligandI309 (CCL1) has been shown to be 
important in the accumulation of monocytes and subsequently macrophages into injured 
livers (191). 
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Though no single chemokine was markedly raised in TNFα treated HSEC compared to 
treatment with LPS there were a number raised with LPS treatment over the levels seen with 
TNFα. Those raised in LPS more than TNFα include: 
ENA 78 
Eotaxin-3 
I-309 
IL-16 
IP-10 chemotactic for monocytes (192) 
MIP-3β 
TARC 
(VCC-1) 
MCP-3 
MIP-3α 
Lymphotaxin 
MDC (CCL22) 
6Ckine 
TARC/CCL17 is a ligand for CCR4 that is found on T-cells selectively and not usually on 
B-cells, natural killer cells or monocytes (193). However in certain inflammatory conditions, 
such as rheumatoid arthritis, monocytes upregulate the expression of CCR4 (194). IL16 and 
6Ckine have been demonstrated not to be chemotactic for monocytes (195, 196). 
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Of particular interest is eotaxin-3/CCL26 which is a member of the CC chemokines and is 
a chemoattractant through CCR3 on eosinophils, basophils and Th2 Lymphocytes. A feature 
of eotaxin-3 is its ability to also bind to CCR2 on monocytes however with differential 
affects to other CCR2 agonists such as monocyte chemotactic protein 1 (MCP-1/CCL2). 
Eotaxin-3 acts as an antagonist for CCR2 inhibiting the typical MCP-1 response of 
intracellular calcium mobilization and activation of mitogen-activated protein (MAP) kinase 
ERK. Furthermore in vitro studies show that monocytes move away from eotaxin-3 
gradients which is amplified by the presence of MCP-1 gradients (197). 
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Figure 4-5. Proteome profiler array of cytokines produced by HSEC.  
HSEC were cultured in media alone or with IFNγ, TNFα or LPS. Supernatants were 
collected and tested on the proteome profiler array in duplicate.  The mean pixel density was 
calculated using Image J software. 
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4.3 Discussion 
 
Toll like receptors are implicated in many chronic liver diseases which are characterised by 
chronic inflammation.  There are a number of mechanisms in the liver that prevent excessive 
inflammation from perpetuation of TLR signalling. These include: 
 Cross tolerance between TLRs altering the expression or activation state of downstream 
signals (198)  
 Local cytokines such as IL-10 are able to modulate TLR pathways (199)  
 The expression of TLRs or its downstream molecules compared to other organs is reduced 
(200)  
 Increased expression of negative regulators of TLR signalling (97) 
In this chapter, we have looked at immunohistochemical staining of TLRs in liver sections 
from normal and diseased livers as the expression reported in the literature varies.  Murine 
studies have shown expression of TLR1-9 at the messenger RNA level and at the protein 
level with generally lower levels of TLR5 compared to the other TLRs (201) (147). Studies 
on human liver tissue have reported inconsistent TLR expression amongst the cell types of 
the liver (Table 4-1). 
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 Szabo, 
Hepatology 
2006 (200) 
Mencin, Gut 
2009 (202) 
Testro, J 
Gastro Hep 
2009 (121) 
Wu, 
Immunology 
2010 (201) 
Hepatocytes  TLR1-9  TLR2 and 4  TLR2-5   
Kupffer  TLR2 and 4  TLR2, 3 and 9  TLR2-4 and 9  TLR2, 7 and 9  
Biliary 
Epithelium  
TLR2,3,4 and 5  TLR1-10  TLR2-5   
Stellate cells  TLR2,3 and 4   TLR4 and 9   
Endothelial 
Cells  
 TLR1-9  TLR4  TLR1-4 and 6-8  
Table 4-1. Literature reported liver TLR expression 
In liver tissue from normal donors the levels of TLRs are lower compared to that of other 
organs (203) adding to the tolerogenic hepatic environment. In samples of normal liver 
tissue, we did not see any staining. However, in samples from diseased livers we have shown 
there is an increase immunohistochemical staining of cell surface expressed TLRs. This was 
the case for diseased livers from PBC, PSC, ALD or AIH. Furthermore, the expression of 
intracellularly expressed TLR9 was also increased in liver disease. This fits with animal 
studies were TLR2, 4 and 9 have been demonstrated to be increased by liver injury (204). 
In the previous chapter we showed that cell surface TLRs could respond to ligands to 
increase the recruitment of monocytes, this was not the case for TLR9. Care however is 
needed, as mentioned earlier TLR immunohistochemistry has a history of being unreliable. 
We then went on to focus on HSEC expression of TLRs by looking at mRNA expression 
and in particular to see the role of stimulation by inflammatory cytokines and LPS. LPS did 
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not alter the expression of all the TLRs in HSEC but did increase TLR2 expression and 
decrease that of TLR4, suggesting some cross-talk. Though the other TLRs were not altered 
that is the possibility there are still functional consequences through downstream signalling 
pathways which are shared by the different TLRs. Alternatively there may be inhibition of 
forming responsive heterodimers. TOLLIP a negative regulator of TLR signalling was not 
altered in these experiments.  
Interestingly the combination of TNFα and IFNγ caused a large rise in TLRs 4 and 7 than 
seen with treatment by these cytokines individually. There was a dramatic increase in 
expression of TLR2, 3 and 5 on HSEC primed initially with TNFα and IFNγ followed by 
LPS, showing a marked synergistic effect of these mediators of inflammation. The synergy 
between TNFα and IFNγ is well appreciated (205, 206). TLR2 usually functions as a dimer 
with TLR1 or 6 but there was no increase in these. The role of TLR3 and the possible reason 
for such an increase if translated to a protein level, is interesting. TLR3 though in out studies 
did not show increased recruitment of monocytes in animal studies have shown the 
recruitment of NK cells and so could be a mechanism by which there is coordination of 
different cell types recruited. TLR3 is also reported to inhibit liver fibrosis by stellate cells 
(207).  TLR5 activation in animal models of liver disease also show a recruitment of NK 
cells different to what is seen with other cell surface TLR agonists (208). TLR5 expression 
on hepatocytes appears to provide some protective effect in fatty liver disease mice models 
(107). It may be that TLR5 expression on HSEC is also a protective response. 
In this chapter, we also looked for reasons other than altered TLR expression to explain the 
differences seen in the migratory ability of monocytes depending on HSEC stimulation. 
Adhesion molecules have functions beyond simply mediating leukocyte adhesion to 
endothelial in the adhesion cascade. Adhesion molecules have the ability to induce signals 
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that influence migration (209). ICAM-1 and VCAM-1 interact with CD11a/CD18, 
CD11b/CD18 and CD49a/CD29 to create “docking structures” involved in migration of 
monocytes (210) (211). Another CD11a/CD18 ligand is ICAM-2 that is expressed on 
endothelial cells. There is some evidence with neutrophils that ICAM-2 also supports 
monocyte migration across HUVEC (56, 212). 
Migration of monocytes is a highly co-ordinated event involving multiple signals and 
interactions between HSEC and monocytes. Studies investigating exogenous chemotactic 
signals on adherent neutrophils to HUVEC have shown that they can disrupt the 
transmigration process without preventing adhesion and accumulation (213). Using ELISA 
of classical adhesion molecules we were unable to note any differences that may explain the 
observations from the previous chapter.  
E-selectin expression on HSEC was increased by LPS and beyond levels seen by pre-
treatment with TNFα together with IFNγ. E-selectin is known to be expressed in vitro by 
HSEC but not in vivo in normal livers but induced in diseased livers(214).  
ICAM-1 and VCAM-1 were upregulated upon LPS stimulation on HSEC. Consistent with 
findings in mice liver sinusoidal endothelial cells (111). TNFα pre-treatment also was able 
to tolerise HSEC to further increase in ICAM-1 expression on exposure to LPS but IFNγ 
was unable to provide cross-tolerance. Pre-treated HSEC also failed to show any increase in 
VCAM-1 expression except if pre-treated with IFNγ alone.  
The constitutively expressed ICAM-2 on in vitro HSEC is not affected by stimulation with 
LPS nor by pre-treatment with TNFα, IFNγ or both in combination.  
The maximal time course expression of ICAM-1 and VCAM-1 varies depending on whether 
the stimuli is shear stress or an alternative stimulus such as LPS. In HUVEC, ICAM-1 is 
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maximally induced by LPS after 18 hours. Shear stress on the other hand maximally induces 
the expression of ICAM-1 within 12 hours which then falls back to basal levels within 24 
hours (215).  Our experiments were carried over time courses of 24 hours and thus some of 
the effects that occur may be lost by the time the assays were performed. 
Also the cell based ELISAs were performed under static conditions. However, shear stress 
can alter the expression of ICAM-1 and VCAM-1(151). 
We went on to use a proteome profiler assay to see whether other factors that are 
differentially regulated between TNFα and LPS stimulation that may explain why despite 
both being potent factors in causing adhesion of monocytes to HSEC out of flow only TNFα 
stimulation results in a significant proportion of monocytes transmigrating. The importance 
of this accumulation and subsequent failure of migration on LPS stimulated HSEC could 
have implication in sepsis. The accumulation may result in a number of possible outcomes 
that include disruption of vascular flow, possible activation and degranulation of toxic 
mediators into the vascular system.  
TNFα stimulated HSEC in this assay did not release any soluble chemokines at levels above 
that were produced by LPS stimulation to account for the increased transmigration seen in 
the flow assays performed in the TNFα stimulated HSEC. Other factors that may be at play 
include immobilisation of the chemokines on activated endothelium, which this assay did 
not assess. For example MCP-1 is not secreted by endothelium in a polarised manner thus 
under conditions of flow the concentration at the luminal side is diminished thus establishing 
a gradient for directing the migration of monocytes (216).  
Studies with HUVEC have shown in particular ENA-78 or GRO-α have the ability to 
prevent efficient transmigration across endothelial monolayers (213). In the studies 
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performed here ENA-78 was markedly increased on LPS treated HSEC and may be of 
significance in partly explaining the differences we have seen in transmigration with 
monocytes.  
 
 
 
  
120 
 
Chapter 5 
5 The Modulation of Monocyte Recruitment on 
HSEC by Fatty Acids 
121 
 
5.1 Introduction 
 
For the purpose of the studies carried out in this work, the two fatty acids used were oleic 
and palmitic acid. Oleic acid is an example of an (mono) unsaturated fatty acid that occurs 
naturally in animals and vegetables including olives as an ester. It is found in higher 
concentrations in Mediterranean diets that are rich in olive oil. Numerous studies have 
demonstrated its health benefit. Oleic acid appears to result in greater steatosis in 
hepatocytes but this triglyceride accumulation appears to be a protective mechanism from 
the lipotoxic effects of free fatty acids (217). Hence oleic acid was chosen in these studies 
to see if the beneficial effects ascribed to it would be evident with an in vitro model of 
hepatic sinusoids. 
Palmitic acid is the most common naturally occurring saturated fatty acid and is found in 
dairy and meat products. It has been ascribed detrimental effects in cardiovascular and liver 
disease (218, 219) through creating a proinflammatory state, and thus was used as an 
example of a saturated fatty acid. 
The aim of this chapter was to see if the fatty acids chosen would alter the recruitment of 
monocytes to HSEC from flow and if there would be a difference between the two fatty 
acids.  
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5.2 Results 
5.2.1 HSEC viability was not reduced by culturing with palmitic acid or 
oleic acid  
The most abundant free fatty acids in humans are oleic and palmitic acid, and thus were 
selected for the following experiments (220). The reported concentration of oleic and 
palmitic acid varies around 144 to 400 μg/ml (equivalent to 50 to 150 μM) (221) to much 
higher levels physiologically dependent upon the population (222, 223). Despite the levels 
of fatty acids that occur physiologically, fatty acids are potentially toxic to cultured cells, a 
phenomenon termed lipotoxicity. Palmitic acid at concentrations as low as 150μM can 
negatively affect the viability of cell lines and endothelial cells (224, 225). Thus, to ensure 
that cultured HSEC could survive dosing with fatty acids, their viability and cell number 
was assessed prior to forward studies.   
 Viability was assessed by trypan blue exclusion and cell number by crystal violet blue 
staining after treating HSEC with 100μM of either oleic or palmitic acid. The presence of 
supplementary oleic or palmitic acid at 100µM resulted in no alteration in survival of HSEC 
or their cell numbers (Figure 5-1Figure 5-1. Measurement of HSEC cell number as assessed 
by crystal violet staining in response to treatment with fatty acids.). 
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Figure 5-1. Measurement of HSEC cell number as assessed by crystal violet staining 
in response to treatment with fatty acids.   
HSEC were treated for 24 hours with 100μM of either palmitic acid or oleic acid. Cell 
number was then assessed by crystal violet staining. Absorbance was measured on an 
automated plate reader (Dynax laboratories, MRX). No difference was seen in cell number. 
Trypan blue staining showed no reduction in cell viability. The data represent the mean ± 
SEM of 4 experiments 
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5.2.2 HSEC treated with Oleic or Palmitic Acid alone do not alter monocytes 
recruitment from flow 
In static adhesion assays of monocyte adhesion on endothelial cell lines, treatment with fatty 
acids leads to increased adhesion (226). To see if HSEC could be independently stimulated 
by fatty acids to modulate recruitment of monocytes out of flow, HSEC were treated for 24 
hours with either oleic or palmitic acid prior to flowing freshly isolated peripheral blood 
monocytes. There was no alteration in adhesion as compared to untreated HSEC (Figure 
5-2). 
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Figure 5-2. Adhesion of monocytes upon HSEC treated with fatty acids.  
HSEC were stimulated for 24 hours with oleic acid (100μM) or palmitic acid (100μM). 
Freshly isolated peripheral blood monocytes were then flown across. The experiment was 
then repeated but with stimulation with LPS (10ng/ml) after pre-treatment with the fatty 
acids. The data represent the mean ± SEM of 4 experiments. There was no significant 
difference seen. 
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5.2.3 Pre-treatment of HSEC with Oleic acid prior to stimulation with LPS 
reduces monocytes adhesion 
Though in themselves the fatty acids did not alter monocytes recruitment in flow assays we 
went on to see if pre-treatment with fatty acids prior to stimulation with LPS on HSEC would 
have an effect, with LPS being a second insult upon the HSEC. Following exposure of HSEC 
with media containing free fatty acid supplementation, the media was changed with further 
media with free fatty acid together with LPS for either 4 hours or 24 hours. HSEC that were 
pre-treated with oleic acid prior to stimulation with LPS resulted in 45% fewer adherent 
monocytes whereas palmitic acid treatment did not change significantly the amount of 
adhering monocytes (Figure 5-3). 
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Figure 5-3. Adhesion of monocytes upon LPS treatment of HSEC pre-treated with 
fatty acids.  
HSEC were stimulated for 24hours with oleic acid (100μM) or palmitic acid (100μM). They 
were then stimulated with LPS (10ng/ml) containing media. Freshly isolated peripheral 
blood monocytes were then flown across. The data represent the mean ± SEM of 4 
experiments. *p<0.05 
 
 
128 
 
5.2.4 Repeated exposure to HSEC to LPS was not able to recapitulate the 
number of monocytes adhering to it 
In the previous chapter, we demonstrated that HSEC showed reduced capacity to capture 
monocytes out of flow after stimulation for 24 hours compared to 4 hours. However further 
stimuli with LPS after 24 hours could increase adhesion though not back to the levels seen 
with a single stimulus for 4 hours. We went on to assess what effect the presence of fatty 
acids would have on this system. Pre-treatment of HSEC with oleic acid suppressed any 
additional recruitment previously seen with repeated LPS stimulation. Palmitic acid did not 
alter the pattern previously seen, in that a further bolus of LPS after 24 hours increased 
adhesion (Figure 5-4). 
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Figure 5-4. HSEC treated with fatty acids response to repeated exposure to LPS upon recruitment of monocytes.  
HSEC were stimulated for 24 hours with oleic acid or palmitic acid. The HSEC were then treated with LPS for 4 hours, 24 hours or 24 hours 
with a further treatment with fresh LPS containing media for an additional 4 hours. Freshly isolated peripheral blood monocytes were then 
flown across. The experiment was then repeated but with stimulation with LPS after pre-treatment with the fatty acids. The data represent 
the mean ± SEM of 3 experiments. *p<0.05
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5.2.5 Flagellin stimulation of fatty acid treated HSEC show similar 
effects with regards to monocytes recruitment as LPS  
Having seen the effect of oleic acid being able to reduce the adherence of monocytes upon 
LPS stimulation of HSEC we went on to see if this effect was maintained by flagellin, which 
signals via TLR5. Oleic acid once again showed an ability to reduce monocytes adhesion 
(Figure 5-5).  
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Figure 5-5. Adhesion of monocytes upon flagellin treatment of HSEC pre-treated 
with fatty acids.  
HSEC were stimulated for 24 hours with oleic acid (100μM) or palmitic acid (100μM). They 
were then stimulated with flagellin after pre-treatment with the fatty acids Freshly isolated 
peripheral blood monocytes were then flown across. The data represent the mean ± SEM of 
3 experiments. *p<0.05 
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5.2.6 Oleic acid and Palmitic acid do not alter the expression of adhesion 
molecules on HSEC or alter the ability of LPS to induce them.  
 
To see if fatty acids are modulating monocyte adhesion through alterations in adhesion 
molecules ELISAs we looked at the adhesion molecules ICAM-1, ICAM-2, VCAM-1 and 
E-selectin using CD31 as a control. Neither oleic acid or palmitic acid altered the expression 
of the adhesion molecules tested nor the ability of LPS to induce the expression of ICAM-
1, VCAM-1 and E-selectin (Figure 5-6).  
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Figure 5-6. Expression of adhesion molecules 
on HSEC by ELISA in response to fatty acid 
treatment.  
 HSEC were stimulated for 24 hours with oleic 
acid (100μM) or palmitic acid (100μM). The 
HSEC media was then refreshed with or 
without were LPS (10ng/ml) for a further 24 
hours. Absorbance was measured on a plate 
reader. The data represent the mean ± SEM of 3 
experiments.  
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5.3 Discussion 
The role of fats in liver disease is complex. The accumulation of fat within the liver does not 
necessarily result in hepatocellular damage. For example, the accumulation of triglycerides 
in the liver is not damaging per se and provides protection from the effects of some free fatty 
acids that are deleterious (227).  
Free fatty acid levels are related to dietary intake including of triglycerides and release from 
adipose tissue.   The Mediterranean diet rich in olive oil decreases fat accumulation in the 
liver (230). The benefit of olive oil is related to the high content of mono unsaturated fatty 
acids principally oleic acid. Mono unsaturated fatty acids decrease serum triglycerides by 
activating peroxisome proliferator-activated receptor (PPAR)α which increases fatty acid 
oxidation and inhibits lipogenesis (230). In animal models of liver cirrhosis, dietary 
modulation with diet rich in oleic acid decreases fibrosis (228). These models have also 
shown reduced insulin resistance and decreased release of fatty acids from adipose tissue 
(229). 
Generally unsaturated fatty acids such as oleic acid are considered to be anti-inflammatory, 
suppressing NF-kB signalling whereas saturated fatty acids such as palmitic acid are 
considered proinflammatory. Importantly fatty acids have been shown to have effects 
through TLR signalling, and in particular with the cell surface TLRs 2, 6 and 4 which is not 
unexpected given that these detect molecular patterns in the cell walls of bacteria in 
particular the lipid components of the cell walls. Palmitic acid has been shown in some 
systems to be capable of activating TLR signalling pathways that result in a pro-
inflammatory state. Not only can fatty acids signalling through the TLR receptors but they 
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may also prevent dimerisation of the receptors which is required before they can signal and 
alterations of the lipid rafts of cells. Saturated fatty acids have been shown to activate TLR4, 
though not directly (231), but possibly through altering receptor numbers (232) or formation 
of dimmers, increasing inflammatory molecules in adipocytes and macrophages (233). On 
the other hand, unsaturated fatty acids may limit TLR activation (234). The effects of fatty 
acids are not limited to TLR4. Dimerisation of TLR2 with either TLR1 or TLR6 to form 
receptors to detect bacterial products, can be enhanced by saturated fatty acids and inhibited 
by polyunsaturated fatty acids (235). 
Previous published work have demonstrated the modulation of the inflammatory response 
of fatty acids on endothelial cells (236). It has been shown that different fatty acids 
depending on whether they are saturated or unsaturated can exert pro- or anti- inflammatory 
effects through modulation of leukocyte adhesion on human saphenous endothelial cells 
(237). In this chapter, we looked at role of fatty acids on monocyte adhesion on HSEC. 
Hepatic sinusoidal endothelial cells are unique with their exposure to portal blood, presence 
of fenestrations, lack of basement membrane and presence of large number of endocytic 
vesicles. The composition of the phospholipid layer of HSEC can also be modified by the 
intake of fatty acids (238). This can have implications for the formation of lipid rafts and 
presentation of receptors on cell surfaces (239). 
Using oleic acid as an example of an unsaturated fatty acid and palmitic acid as a saturated 
fatty acid at physiological doses HSEC in our studies maintained their viability. The culture 
of HSEC with either of these fatty acids for 24 hours did not alter the adhesion of monocytes. 
However only a single concentration was used in these experiments and there is a wide 
variability in the concentration of these fatty acids in the population. It is possible if different 
concentrations were used, differences may have become apparent.   
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Previously the role of endotoxin and fatty acids in the role of liver inflammation and damage 
has been described through the two hit hypothesis of non-alcoholic steatohepatitis (240). 
This consists on an initial hit from excessive fatty acids and the accumulation of fat in the 
liver. This fat accumulation sensitises the liver to further insults that include that of 
endotoxin. In animal models inhibition of TLR4 signalling in animal models of fatty liver 
disease accentuates the inflammation (241). Adding to this, fatty livers are poor at clearing 
LPS thus allowing it to enter into the systemic circulation in greater quantities, having 
implication for sepsis (242). Peripheral adipose tissue exposure to LPS stimulates further 
TNFα and free fatty acid release which feedbacks to liver causing more damage. Fatty livers 
are also more sensitive to the effects of LPS (242). 
Flow assays were performed to see if an additional insult in the form of exposure to LPS 
would modify monocytes recruitment on fatty acid pre-treated HSEC. Only the presence of 
oleic acid in the HSEC culture medium prior to stimulation with LPS altered the recruitment 
of monocytes by decreasing the number of adherent monocytes captured from flow. 
Furthermore, pre-treatment with oleic acid reduced the responsiveness of HSEC that had 
already been cultured with LPS for 24 hours which were then treated with a further 4 hours 
of fresh LPS containing media unlike in Chapter 3 were there was an increase when there 
was no oleic acid treatment. Palmitic acid did not have a significant effect. 
Looking at adhesion molecules, studies using HUVEC, preincubation with palmitic acid 
does not result in altered expression of the adhesion molecule VCAM-1 upon exposure to 
LPS. Whereas oleic acid preincubation, suppressed expression upon LPS stimulation, but 
only after prolonged treatment (236). In this study the expression of adhesion molecules on 
HSEC cultured in fatty acids was not altered.  It is possible as seen in other studies that this 
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was because there was not sufficient time to allow for changes to occur and if a longer time 
point had been used, changes may have been seen.     
The saturated fatty acid palmitic acid has been shown to be pro-inflammatory in different 
cell lines (235, 239, 243) through the activation of TLR2 and 4 pathways. However, the 
proinflammatory effects using palmitic acid were not seen in the experiments performed on 
HSEC in this chapter. HSEC cultured in palmitic acid did not demonstrate increased 
adhesion molecule expression nor increased monocyte adhesion in flow. Nor was there 
alteration in adhesion following stimulation with LPS or flagellin.  
Although these studies have not shown the pro-inflammatory potential of palmitic acid in 
this model of monocyte recruitment it does not exclude their inflammatory potential through 
other mechanisms including potentially recruiting other leukocytes. This study does add to 
the documented beneficial effects of oleic acid, by reducing, but not abolishing recruitment 
of monocytes in response to inflammatory stimuli from both TLR4 and 5 agonists.  
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Chapter 6 
6 Phenotypic and Functional Changes of Kupffer 
Cells in Response to Inflammation and Fatty Acids 
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6.1 Introduction 
So far, this thesis has concentrated on the recruitment of monocytes by HSEC. One of the 
fates of recruited is the differentiation into macrophages. Macrophages are highly plastic 
cells and depending on environment have different phenotypes with different roles.  
The aim of this chapter is to see the if the stimulation of human liver derived macrophages 
with inflammatory cytokines and fatty acids change the expression of phenotypic markers 
and TLR expression. We also attempted to build a more representative model of hepatic 
sinusoids with co-culturing of HSEC with liver derived macrophages. 
6.2 Phenotype of liver derived macrophages 
To determine if human liver derived macrophages retain the plasticity to change phenotype 
in response to external stimuli they were cultured for 24 hours with media containing LPS, 
TNFα, IFNγ or IL-4. IL-4 has the ability to result in alternatively activate macrophages. 
Mannose receptor (CD206) is a marker of M2 alternative activation of macrophages and 
consistent with IL-4 stimulation resulted in increased expression of CD206 on IL-4 
stimulated liver derived macrophages. CD163, a haptoglobin-haemoglobin scavenger 
receptor, is also a marker of alternative activation. Previous studies have shown that on 
macrophages derived from human peripheral monocytes express high basal levels of 
CD163; however exogenous IL-4 stimulation suppresses its expression. Liver derived 
macrophages treated with IL-4 demonstrated a similar behaviour to monocytes derived 
macrophages with suppression of CD163 expression (Figure 6-1). TNFα and LPS 
stimulation also suppress CD163 expression in liver derived macrophages (Figure 6-1) as 
seen with monocytes derived macrophages (244). 
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LPS stimulation of liver derived macrophages resulted in upregulation of CD16, a low 
affinity Fc receptor involved in binding antibodies. CD16 has been shown to have the ability 
to regulate TRIF dependent TLR4 signalling pathway and enhance the response to gram 
negative sepsis (245). 
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Figure 6-1. Phenotype of liver derived macrophages in response to external stimuli.  
Liver derived macrophages were treated with either LPS, TNFα, IFNγ or IL-4. Phenotype 
markers were assessed by relative real time PCR and compared to untreated liver derived 
macrophages. The results represent the mean ± SEM of three experiments with different 
donors performed in triplicate. *p<0.05 
142 
 
6.2.1 Oleic acid is able to increase CD206 expression on liver derived 
macrophages, a marker of alternative activation 
Kupffer cells are involved in lipid metabolism. Alternatively activated Kupffer cells are 
postulated to have a beneficial effect on metabolic syndrome and type II diabetes (246). 
Thus to see if human liver derived macrophages would respond to fatty acids they were 
treated with palmitic or oleic acid for 24 hours. Oleic acid was able to up regulate CD206 
consistent with taking on a more alternatively activated phenotype (Figure 6-2). 
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Figure 6-2. Phenotype of liver derived macrophages in response to fatty acids.  
Liver derived macrophages were treated with either oleic (100µM) or palmitic acid 
(100µM). Phenotype markers were assessed by relative real time PCR and compared to 
untreated liver derived macrophages. The results represent the mean ± SEM of three 
experiments with different donors performed in triplicate. *p<0.05 
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6.2.2 TLR expression of liver derived macrophages after cytokine 
stimulation 
To see if treatment of liver derived macrophages would have a subsequent effect upon TLR 
expression, once again stimulation was performed with LPS, TNFα, IFNγ and IL-4. TLR2 
expression was upregulated in response to LPS; however LPS (nor the other cytokines) 
effected the expression of TLR4 at an RNA level. IL-4 was able to upregulate TLR5 
expression. TNFα and IFNγ increased the expression of TLR 7 and 8. The inhibitory protein 
TOLLIP was not altered by any of the treatments (Figure 6-3). 
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Figure 6-3. TLR expression in liver derived 
macrophages.  
Liver derived macrophages were treated with 
either LPS, TNFα, IFNγ or IL-4. TLR mRNA 
expression was assessed by relative real time 
PCR and compared to untreated liver derived 
macrophages. The results represent the mean ± 
SEM of three experiments. *p<0.05 
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6.2.3 Liver derived macrophages can be co-cultured with HSEC 
Liver sinusoids do not only consist of HSEC but also Kupffer cells which are in close 
proximity to each other and have the ability to alter each other’s functionality. To see if we 
could build up a more representative model of this situation we co-cultured liver derived 
macrophages with HSEC and demonstrated we were able to maintain the two cell types in 
culture using endothelial media (Figure 6-4). 
  
148 
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Figure 6-4. Co-culture of HSEC with liver derived macrophages 
Liver derived macrophages were isolated and cultured in 96 well plates. Once the 
macrophages had been established in culture after 24 hours,  HSEC were plated in to the 
wells. The images show samples of co-cultures together with CD68 staining to highlight the 
macrophages, and the cells cultured alone. 
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6.2.4 Co-culturing human liver derived macrophages with HSEC did not 
alter cell numbers 
There are studies that have demonstrated the ability of macrophages to alter the 
proliferation of endothelium and depending on any other exogenous stimuli this can be 
either proliferative or inhibitive (247, 248).  To ensure that there was no alteration in cell 
numbers that may account for some of the differences seen in the expression of adhesion 
molecules crystal violet proliferation assay was carried out. The value obtained remained 
steady though co-culturing and upon cytokine stimulation (Figure 6-5). 
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Figure 6-5. Cell number upon co-culturing HSEC with liver derived macrophages. 
Crystal violet staining was used to assess cell number after culturing HSEC with liver 
derived macrophages. Absorbance was measured on a plate reader and the values represent 
the mean ± SEM of 3 experiments. 
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6.2.5 ICAM-1 is increased by co-culture of HSEC with liver derived 
macrophages, whilst VCAM-1 is reduced 
As Kupffer cells are key components in the structure of sinusoids, the effect of co-culturing 
liver derived macrophages with HSEC on the expression of adhesion molecules was 
investigated. Liver derived macrophages were plated initially in to 96 well plates and after 
24 hours HSEC were plated on top. The expression of adhesion molecules was then assessed 
and including after stimulation with TNFα and IFNγ or LPS. In co-cultures the basal levels 
of ICAM-1 and E-selectin were raised. However, unlike stimulation with LPS or TNFα and 
IFNγ on monocultures of HSEC which caused increased expression of ICAM-1 and E-
selectin, in the co-cultures no further increase in expression was demonstrated by stimulation 
with LPS or TNFα and IFNγ. ICAM-2 levels did not alter with co-culturing or stimulation 
with LPS or TNFα. Interestingly VCAM-1 levels were reduced in co-cultures of HSEC with 
liver derived macrophages. Once again stimulation of the co-cultures with TNFα and IFNγ 
or LPS had no effect on the expression of the adhesion molecule VCAM-1 (Figure 6-6).  
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Figure 6-6. Expression of adhesion 
molecules in co-cultures of HSEC with liver 
derived macrophages.  
HSEC were plated on to liver derived 
macrophages. They were then treated once 
established with LPS or TNFα. The data 
represent the mean corrected absorbance ± 
SEM of three independent experiments. 
*p<0.05 
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6.2.6 Human liver derived macrophages are unable to support adhesion 
out of flow 
To determine if Kupffer cells in their own right were able to recruit monocytes out of flow, 
human liver derived macrophages were cultured in IBDI slides, however they rapidly 
perished. Eventually we were able to get maintain them on coverslips and mount them in 
parallel chambers. Then peripheral blood monocytes were flowed across (Figure 6-7). No 
attachment was seen. Even when the liver derived macrophages were stimulated with TNFα 
or LPS, monocytes still did not adhere. To investigate whether in co-cultures with HSEC 
any difference would be seen, given that the previous set of experiments had shown altered 
expression of adhesion molecules, attempts were made to culture the two cell groups. 
However, it proved challenging to get the HSEC to grow alongside liver derived 
macrophages to create a monolayer to perform flow assays on reliably. 
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Figure 6-7. Still from monocytes flowing over liver derived macrophages. 
Liver derived macrophages were cultured on coverslips to form a monolayer. The 
coverslips were then mounted in a parallel chamber and monocytes were then flowed 
across. 
  
Monocytes 
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6.3 Discussion  
Kupffer cells are strategically located and form together with HSEC the liver sinusoids. They 
are more numerous in the periportal regions of the liver (249). Kupffer cells are well 
recognised as mediators of liver damage and resolution as well as maintaining homeostasis. 
Kupffer cells make up 90% of body macrophages (21) and 15-20% of the liver cells (22). 
Kupffer cells are motile cells characterised by a large nucleus, significant amounts of rough 
endoplasmic reticulum and cytoplasmic vacuoles, reflecting their functions. They are highly 
phagocytic cells, able to engulf a range of pathogens, cell and antigens that include bacteria, 
viruses, red blood cells, tissue debris and certain tumour cells (250). 
Given the multitude of roles Kupffer cells play it is not unsurprising that they take on 
different phenotypes to fulfil each role. The main subdivision is between M1 classically 
activated forms and M2 alternative activation with further subtypes depending upon the 
stimuli. Despite classification of macrophages into subtypes, the reality is likely to be the 
phenotype of macrophages is a spectrum of a highly plastic cell population that are able to 
differentiate depending on stimuli and back again.   
M1 (classical) macrophages occurs in response to microbial products or interferon-gamma 
and results in high production of IL-12 and IL-23 (and low IL-10) (251). M1 macrophages 
have a high capacity to present antigen and to produce factors that promote T-cell 
proliferation and activity. Also there is a high production of toxic intermediates namely nitric 
oxide (via increased levels of inducible NO synthase) and reactive oxygen intermediates. 
They express opsonic receptors (e.g. CD16/FcyRIII). M1 macrophages are potent effector 
cells that kill micro-organisms and tumour cells, present antigens and produce 
proinflammatory cytokines (252). 
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On the other end of the spectrum M2 (alternatively activated) macrophages have poor 
antigen-presenting capability; produce factors that suppress T-cell proliferation and activity. 
They express preferentially non-opsonic receptors (e.g. mannose receptor) and scavenger 
receptor. M2 macrophages have a predominant activation of the arginase pathway resulting 
in the production of ornithine and polyamines. They produce higher levels of IL-10 high. 
They are thought to be important in debris scavenging, wound healing, and angiogenesis. 
M2 macrophages may also play key roles in chronic infections, tumourgenesis, and tumour 
metastasis (253). 
Under the influence of IL-4 the population of resident tissue macrophages can expand, and 
IL-4 is associated with the ability to differentiate macrophages in to alternatively activated 
macrophages required for resolution and repair of tissue damage (254). The liver derived 
macrophages we isolated, upon stimulation with IL-4 up regulated the expression of CD206 
in keeping with their alternatively activated phenotype. Furthermore, oleic acid also 
increased CD206 pushing the macrophages towards an alternatively activated phenotype. 
Palmitic acid had no effect on the expression of CD206.  
Macrophages are well described as being particularly plastic cells, readily altering their 
phenotype according to environmental cues.  Additionally following polarisation they are 
able to upon further stimulation polarise into a different phenotype and back again (264). 
This plasticity of macrophages allows them to undertake diverse and contrary functions. 
Macrophages are thus able to dynamically change the polarisation through the course of 
inflammatory processes without the need to recruit further pre-polarised macrophages (265). 
We were able to push the expression of phenotype markers of liver derived macrophages 
including with IL-4 to a more alternatively activated phenotype. We were also able to induce 
an alternatively activated phenotype using oleic acid. We were unable to induce significant 
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changes with palmitic acid. However work by others have shown that palmitic acid treated 
Kupffer cells produce more TNFα compared to media or oleic treated Kupffer cells (266). 
Due to the location of Kupffer cells in relation to the hepatic sinusoids and exposure to portal 
blood containing gut derived pathogens, the expression of TLR was assessed in response to 
inflammatory stimuli namely TNFα and LPS which causes classical activation and IL-4 
which alternatively activates. Of particular note was the change in TLR5 expression with 
IL-4 treatment which was in line with the findings from other groups on macrophages (255). 
Why only TLR5 increased in response to IL-4 is open to speculation. A possibility is that is 
a mechanism by which the innate and adaptive immune system are linked and coordinated. 
There are recent studies looking at the role of flagellin in vaccines. Flagellin is required to 
induce activation of adaptive responses (256). Research in inflammatory bowel disease 
suggest that flagellin may responsible through adaptive response create a state of chronic 
inflammation (257). 
Looking at the functional role of Kupffer cells, it is known that they can interfere with the 
flow through sinusoids (258) including inducing the temporary stasis of sinusoidal blood 
flow thus allowing for prolonged contact between the leukocytes and sinusoids. It has been 
shown that Kupffer cells are capable of directly capturing and recruiting dendritic cells from 
the circulation (259). It has also previously been documented in flowing systems that 
Kupffer cells are able to capture neutrophils out of flow (260). There are important direct 
cell to cell interaction with Kupffer cells and other leukocytes such as NK cells. Kupffer are 
able in the endotoxic environment to arrest the flow of platelets (261).  
We attempted initially to use Ibidi slides to culture liver derived macrophages but they would 
rapidly perish. Eventually we were able to establish them on coverslips to use in parallel 
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flow chambers. Monolayers of liver derived macrophages on coverslips could not capture 
monocytes out of flow even after stimulation with LPS or TNFα.  
Macrophages, together with neutrophils and monocytes despite their common origin are 
complementary in the actions and interactions. Macrophages are long lived and resident in 
tissues with greater specificity in antigen recognition. Due to their strategic location within 
tissues they are ideally situated to initiate inflammation in response to attack. Part of the 
response is the production of chemokines directed at recruiting the potent antimicrobial 
neutrophils. Additionally the degranulation of neutrophils releases proteins that have a 
multifactorial effect including the promotion of further chemokine production by 
macrophages, conversion of chemokines to pro-forms, activation of endothelium and 
anchoring to endothelial proteoglycans which all work in concert to recruit classical 
monocytes (262, 263). So though we did not see any direct interaction of Kupffer cells with 
flowing monocytes additional factors may be involved and this model was too reductionist. 
Another limitation with these experiments once again was the use of monocytes from one 
donor and liver derived macrophages from another. 
Furthermore, even within the liver, Kupffer cells vary. Kupffer cells within the periportal 
area of the liver are larger and more phagocytic whereas the smaller Kupffer cells in the 
centrilobular areas are more avid cytokine producers (20, 249) and in our experiments there 
were no attempts to isolate different types of Kupffer cells.  
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Chapter 7 
7 Discussion 
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7.1 General Discussion 
Liver disease continues to be a significant and increasing socio-economic burden. Liver 
disease as it progresses share some certain common hallmarks, that includes being in a state 
inflammation with an associated inflammatory infiltrate resulting in damage. The ability to 
isolate primary human cells provides the ability to dissect the complex interactions that 
occur within the liver, to better understand these processes.  
The liver has evolved the ability to tolerate numerous and varied insults. However multiple 
hits can result in progressive and irreversible liver damage. Part of this multi-hit milieu 
involves microbial products and fatty acids together with interactions involving TLRs.  The 
gut acts as a source of microbial products that are potential sources of inducing a septic 
inflammatory response, with effects on the liver and further systemically. The gut also is 
responsible for uptake of nutrients from the diet which includes fatty acids. Through these 
products, the gut is intimately linked to the liver. Microbial products and fatty acids are able 
to alter the state of hepatic sinusoids, a key gate keeper to the parenchyma of the liver in 
particular leukocytes that are crucial in mediating liver injury (as well as resolution)..   
One of the leucocyte type involved in mediating inflammation, are monocytes which are 
highly plastic cells with not only the ability to be effectors in their own right, but also the 
ability to differentiate into Kupffer and dendritic cells. In this piece of work we have aimed 
to look at some of the interactions of microbial TLR agonists and fatty acids upon 
recruitment of monocytes upon HSEC. 
Multiple researchers have shown a close relation between bacterial products and in particular 
LPS in not only being critical in the development of liver disease but also promoting its 
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progression. LPS acts via TLR4, however is efficiently cleared from the portal blood stream 
during health without triggering an overwhelming inflammatory response.  
The use of flow assays in this studies showed that HSEC exposed to LPS similar to the 
inflammatory cytokine TNFα is able to result in a pro-adhesive state that is able to recruit 
monocytes out of flow and similarly as observed previously with other leukocytes, no 
significant rolling was seen before firm adhesion. However, there is a notable difference in 
that the adherent monocytes on LPS treated HSEC. These monocytes in this study did not 
show as extensive transmigration through the LPS treated HSEC monolayers compared to 
TNFα treated HSEC. The significance of this may reflect what occurs in normal healthy 
individuals that despite the constant presence of endotoxin from the gut, the liver is not 
flooded by an influx of monocytes and the potentially deleterious effects. Also noted was 
that with longer incubation the number of monocytes captured decreased, again adding to 
the tolerogenic environment.  
In these studies, we have been able to demonstrate that the effects seen are not unique to 
LPS and that another TLR4 agonist, namely MPL is able to produce similar results. We have 
also been able to expand this finding showing that agonist to other cell surface TLRs 
including flagellin, are able to stimulate HSEC to be able to recruit monocytes and again 
with minimal transmigration.  
Monocytes have been observed to exhibit a “patrolling” behaviour on the luminal surface of 
the liver vasculature (33) without infiltrating deeper and this fits in with the observations 
seen that healthy adults have endotoxin present in the portal blood stream without causing 
influx of monocytes. We did not look at whether alterations in concentration of LPS or the 
other TLR ligands have an effect within the modelled sinusoidal system. The relevance of 
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this lies with the increase presence of microbial products transported to the liver in liver 
disease due to an increase permeability of the gastrointestinal tract. It would be useful to 
know if higher concentrations would result in more transmigration of monocytes across 
HSEC.   
Work by others has reported that stimulation of murine TLR5 does not result in TNFα 
production (201) and taken as meaning liver sinusoidal endothelial cells are unresponsive to 
TLR5 stimulation (267). Our studies on primary human HSEC has shown that flagellin does 
have a functional consequence, namely in this set of studies the ability to recruit monocytes 
out of flow. This is consistent with murine studies with looking at alcoholic liver disease 
where the administration of flagellin results in an inflammatory infiltrate (268).  
TLR5 mRNA expression in HSEC and liver derived macrophages was interesting in the 
marked increased expression when these cells were stimulated. TLR5 expression was 
increased on HSEC by stimulating these cells with LPS after initially priming with TNFα 
and IFNγ showing a synergistic effect. Liver derived macrophages increased TLR5 
expression on IL-4 stimulation. Whether this is of functional consequence is dependent on 
whether the mRNA is translated and if so what is its significance when the mRNA 
expression of the other TLRs did not change to the same extent.  
We also looked at what happened when monocytes were exposed to cell surface TLR ligands 
rather than hepatic endothelium. Upon stimulated inflamed endothelium, by treating with 
TNFα and IFNγ, there was a significant reduction in the proportion of adhering monocytes 
migrating across the endothelium.  
There are limitations in the flow assays we performed in particular to the modelling of 
hepatic environment. The use of static flow rates does not accurately model the true flow 
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that occurs as liver disease progresses. Haemodynamic changes occur that include 
diminished portal venous blood flow (269). Also, though certain experiments showed no 
changes in adhesion they may still have a role through interactions with other cell types not 
included with these setups. However, these models do provide a mechanism by which 
complex interactions can be broken down and explored.  
A further limitation of the experiments performed is that endothelial cells are outside of their 
native environment and detached from their usual environmental context and thus undergo 
phenotypical and physiological changes. Usually they are exposed to a multitude of external 
stimuli, including flow, neural and hormonal influences. They display spatial and temporal 
variability. In septic patients further haemodynamic, oxygenation levels and acidity changes 
occur (270). In an attempt to recreate a more accurate simulated hepatic sinusoid we were 
able to demonstrate that it is possible to co-culture liver derived macrophages together with 
HSEC. We were however unable to get the co-culture to establish in Ibidi slides, however 
to overcome this we eventually used coverslips in parallel flow chambers though this was 
still unreliable.  
Endothelium interaction with monocytes goes beyond recruitment. In co-culture 
experiments it has been shown that monocyte survival increases with interaction with LPS 
and other inflammatory cytokine activated endothelial cells. Furthermore CD14 expression 
is upregulated as well as of chemokines such as MCP-1 potentially recruiting further 
monocytes (271, 272). 
In this work, we have also looked at the role of fatty acids and in particular the differences 
that have been reported between saturated and unsaturated fatty acids. Though we were 
unable to demonstrate a pro-inflammatory effect of palmitic acid we were able to show that 
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oleic acid was able to reduce the recruitment of monocytes upon modelled inflamed hepatic 
endothelium. Oleic acid was also able to differentiate liver derived macrophages to an 
alternatively activated phenotype which has been implicated in liver tolerance and repair.  
 
7.2 Summary 
In conclusion, bacterial ligands and fatty acids are critically integrated together being taken 
up from the gut in the pathogenesis of liver disease. Linking the two are toll-like receptors. 
Microbial ligands are able to support adhesion to HSEC, but to migrate across the 
endothelium require priming. Oleic acid is able to suppress monocytes recruitment to 
inflamed endothelium (Figure 7-1). 
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Figure 7-1. Summary of the liver-gut axis in recruiting monocytes. 
Microbial and fatty acid products from the gut are able to modulate the recruitment of monocytes to the liver out of flow. 
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7.3 Future work 
Kupffer cells form an integral part of the hepatic sinusoids, lying on the luminal side and 
thus exposed to the flow of blood. Due to their size and ability to undergo morphological 
changes they can alter flow through sinusoids (273, 274). Kupffer cells have been 
demonstrated to interact with leukocytes, namely neutrophils through complimentary 
adhesion molecules (260) and that upon depletion reduce the recruitment of neutrophils into 
the liver (275). Furthermore the depletion of Kupffer cells reduces the recruitment of 
monocytes into the liver through possibly reduced expression of MCP1 (276). It would be 
interesting to go on and further develop reliable co-culture models of Kupffer cells and 
HSEC attempted here to see if different conditions can modulate recruitment of monocytes 
from flow. Ideally one would isolate all the cell types from a single donor.  
Monocytes have been shown to not only migrate across endothelium but reverse 
transmigrate. Using CELL-IQ an automated cell culture and analysis system, though under 
static conditions, initial experiments on monocytes demonstrate qualitatively different 
behaviours depending on the treatment of HSEC. With advances in technology and 
processing offered through CELL-IQ if would be interesting to track monocytes in 
continuous flow over prolonged time frames and assess their phenotype over the time course 
to see if they take on more of dendritic phenotype or that of a macrophage. Work in our lab 
has already shown some changes that occur with monocytes as they migrate across 
endothelium (277). 
Finally, it would be interesting to explore further the roles of eotaxin and ENA-78 that are 
produced differentially depending on HSEC stimulation with TNFα or LPS and whether 
they do have the inability to block migration of monocytes.  
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